

Cohorte ANRS CO3 Aquitaine

Publications scientifiques 1989 - 2020

I. Liste complète des publications scientifiques (hors thèses)

p 2

N = 455

Classées par année et par ordre alphabétique du premier auteur

[1989](#), [1990](#), [1991](#), [1992](#), [1993](#), [1995](#), [1996](#), [1997](#), [1998](#), [1999](#), [2000](#), [2001](#), [2002](#), [2003](#),
[2004](#), [2005](#), [2006](#), [2007](#), [2008](#), [2009](#), [2010](#), [2011](#), [2012](#), [2013](#), [2014](#), [2015](#), [2016](#), [2017](#), [2018](#),
[2019](#), [2020](#)

II. Listes des publications par collaboration internationale

Classées par année et par ordre alphabétique du premier auteur

II.1. ART-CC, Antiretroviral Therapy Cohort Collaboration

[p 47](#)

N = 33

II.2. CASCADE,

Concerted Action on SeroConversion to AIDS and Death in Europe

[p 52](#)

N = 41

II.3. COHERE / Eurocoord

Collaboration of Observational HIV Epidemiological Research Europe

[p 57](#)

N = 45

II.4. DAD, Data Collection on Adverse Events of Anti-HIV Drugs

[p 63](#)

N = 66

II.5. EuroSIDA (à partir de 2004)

[p 71](#)

N = 83

II.6. Autres collaborations

[p 79](#)

N = 26

I. Liste complète des publications (hors thèses de doctorat)

N = 455 (sauf 27 résumés publiés dans des suppléments de périodiques français à l'occasion de congrès)

Classées par année et par ordre alphabétique du premier auteur

1989

Morlat P, Msellati P, Dupon M, Pellegrin JL, Lacoste D, Gecsa. Aspect pronostique des adénopathies persistantes au cours de l'infection par le virus de l'immunodéficience humaine. *Presse Med* 1989;18(34):1710-1711

1990

Chêne G, Parneix P, Dabis F, Salamon R, Gecsa. Surveillance hospitalière de l'infection par le VIH, Bordeaux, 1983-1989. *BEH* 1990(18):77-79

Dabis F, Poumerol G, Chêne G, Chaslerie A, Msellati P, Commenges D, Salamon R, Gecsa. Surveillance hospitalière de l'infection par VIH à Bordeaux : tendances épidémiologiques, 1985-1989. *Sante Publique* 1990;2(1):29-30

Msellati P, Dupon M, Morlat P, Lacoste D, Pellegrin JL, Dabis F, Gecsa. A cohort study of 89 HIV-1 infected patients contaminated by blood products : Bordeaux (France) 1981-1989. *AIDS* 1990;4(11):1105-1110

1991

Chêne G, Morlat P, Commenges D, Dupon M, Parneix P, Brossard G, Lacoste D, et le G. Evolution clinique de 763 sujets infectés par le VIH : étude de l'influence du mode de contamination. Bordeaux, France 1985 - 1990. *Med Mal Infect* 1991;21(7):406-410

Dabis F, Chêne G, Salamon R, Msellati P, Etcheverry B, for the G. Hospital-based surveillance of HIV infection: Bordeaux, France, 1983-1990. *AIDS* 1991;5(6):772-775

Dupon M, Bismuth MJ, Parneix P, Morlat P, Malou M, Gecsa. Infection par le virus de l'immunodéficience humaine chez les personnes âgées de plus de 60 ans. Une étude de cohorte de 31 patients suivis au CHRU de Bordeaux. *Rev Med Interne* 1991;12(6):419-423

Msellati P, Checkouri G, Ragnaud JM, Dupon M, Brossard G, Lacoste D, Gecsa. Importance de la contamination hétérosexuelle dans l'infection par le VIH, Bordeaux, 1985-1990. *Presse Med* 1991;20(2):83.

Morlat P, Chêne G, Ragnaud JM, Lacoste D, Dupon M, Pellegrin JL, Gecsa. Principales caractéristiques épidémiologiques de la candidose oesophagienne au cours du SIDA (Bordeaux, 1985-1990). *Presse Med* 1991;20(2):2265.

1992

Chêne G, Dabis F, Salamon R, Gecsa. Hospital-based surveillance of HIV infection : epidemiological trends, Bordeaux France, 1983-1989. *Eur J Epidemiol* 1992;8(1):58-66

Chêne G, Morlat P, Dabis F, Gecsa. Impact of revision of AIDS case definition. *Lancet* 1992;339(8804):1298-1299

Constans J, Ladner J, Dabis F, Brossard G, Commenges D, Leng B, Conri C, Gecsa. Hyperlymphocytose CD8 au cours de l'infection par le VIH : étude d'une cohorte de 63 patients ; Bordeaux, 1985-1989. *Presse Med* 1992;21(1):27-30

Hajjar M, Lacoste D, Brossard G, Morlat P, Dupon M, Salmi LR, Dabis F, Gecsa. Non-AIDS defining malignancies in a hospital-based cohort of HIV-infected patients : Bordeaux (France), 1985-1991. J Natl Cancer Inst 1992;84(20):1593-1595

Ladner J, Brossard G, Dabis F, Morlat P, Rogues AM, Gecsa. Séroprévalence de l'hépatite C chez les sujets infectés par le VIH. Presse Med 1992;21(5):219.

Morlat P, Parneix P, Douard D, Lacoste D, Dupon M, Chêne G, Pellegrin JL, Ragnaud JM, Dabis F, Gecsa. Women and HIV infection : a cohort study of 483 HIV-infected women, Bordeaux, France, 1985-1991. AIDS 1992;6(10):1187-1193

1993

Baldi I, Morlat P, Chêne G, Dupon M, Lacoste D, Monlun E, Ragnaud JM, Dabis F, Gecsa. Evolution des caractéristiques cliniques et immunologiques au moment du diagnostic de SIDA : résultats de la Cohorte Aquitaine, 1985-1991. Med Mal Infect 1993;23(12):902-907

Chêne G, Dabis F, Salamon R, Gecsa. La tuberculose chez les patients infectés par le VIH en Aquitaine. BEH 1993(15):66-67

Ragnaud JM, Morlat P, Dupon M, Lacoste D, Pellegrin JL, Chêne G, Gecsa. Toxoplasmose cérébrale au cours du SIDA. 73 observations. Presse Med 1993;22(19):903-908

Ragnaud JM, Morlat P, Dupon M, Pellegrin JL, Lacoste D, Monlun E, Chêne G, Aubertin J, Gecsa. Rechutes de toxoplasmose cérébrale au cours du SIDA. Etude de 25 cas. Med Mal Infect 1993;23(11):791-795

1995

Dupon M, Texier-Maugein J, Leroy V, Sentilhes A, Pellegrin JL, Morlat P, Ragnaud JM, Chêne G, Dabis F, Gecsa. Tuberculosis and HIV infection: a prospective cohort study of incidence and susceptibility to antituberculous drugs, Bordeaux (France), 1985-1993. AIDS 1995;9(6):577-583

Hocke C, Morlat P, Chêne G, Dequae L, Dabis F, Gecsa. Prospective cohort study of the effect of pregnancy on the progression of HIV infection (France), 1985-1994. Obstet Gynecol 1995;86(6):886-891

Lasseur C, Maugein J, Pellegrin JL, Dupon M, Ragnaud JM, Morlat P, Pellegrin I, Constans J, Monlun E, Chêne G, Leng B, Gecsa. Infections généralisées à mycobactéries du complexe aviaire au cours du SIDA. A propos de 100 observations. Rev Med Interne 1995;16(2):110-120

Morlat P, Helmer C, Chêne G, Bernard N, Monlun E, Beylot J, Dabis F, Gecsa. Surveillance of heterosexually acquired HIV infection and AIDS. Lancet 1995;346(8970):308-309

Morlat P, Hubert JB, Chêne G, Buisson M, Paty MC, Lasseur C, Constans J, Bernard N, Gecsa. Effet de la prophylaxie primaire de la pneumocystose pulmonaire sur la présentation clinique et biologique inaugurale du SIDA : 624 observations (Cohorte Aquitaine, 1985-1994). Rev Med Interne 1995;16(11):815-817

1996

Bernard N, Merchadou L, Dabis F, Lacoste D, Gecsa. Prophylaxie du CMV : la prescription erratique du ganciclovir oral. J SIDA 1996(91):7.

de Chabaliér F, Decoin M, Bonarek M, Ortega V, Marimoutou C, Dabis F. Hospital-based surveillance and emerging patterns of HIV transmission. AIDS 1996;10(5):551-552

Helmer C, Morlat P, Dabis F, Chêne G, Ragnaud JM, Dupon M, Pellegrin JL, Monlun E, Gecsa. Transmission hétérosexuelle de l'infection par le VIH en Aquitaine. Résultats d'un système de surveillance hospitalier, 1985-1993. Med Mal Infect 1996;26(10):832-838

Lacoste D, Marimoutou C, Dabis F, Garros B, Renaud F, Gecsa. Décroissance de l'incidence de l'infection à VIH chez les toxicomanes intra-veineux en Aquitaine : 1985-1993. Presse Med 1996;25(22):1018-1022

Morlat P, Chêne G, Ragnaud JM, Mercié P, Grobost F, Bernard N, Lacoste D, Beylot J, Aubertin J. Decreased serum concentrations of Tumor Necrosis Factor-alpha in HIV-infected individuals treated with zidovudine. Pathol Biol 1996;44(8):716-719

Morlat P, Dequae-Merchadou L, Dabis F, Chêne G, Salamon R, Beylot J, Gecsa. Splenectomy and prognosis of HIV infection. AIDS 1996;10(10):1170-1172

Saillour F, Dabis F, Dupon M, Lacoste D, Trimoulet P, Rispal P, Monlun E, Ragnaud JM, Morlat P, Pellegrin JL, Fleury H, Couzigou P, Gecsa. Prevalence of hepatitis C virus antibody and serological markers of hepatitis B virus infection in the Aquitaine Cohort of HIV-infected patients, 1991-1994. BMJ 1996;313(7055):461-464

Saillour F, Dupon M, Pellegrin I, Couzigou P, Dabis F, Gecsa. Prévalence des marqueurs sérologiques du VHC et du VHB dans la Cohorte Aquitaine de patients infectés par le VIH. Med Mal Infect 1996;26(5):548-550

1997

Dousset V, Armand JP, Lacoste D, Mieze S, Letenneur L, Dartigues JF, Caille JM, Gecsa. Magnetization transfer study of HIV encephalitis and progressive multifocal leukoencephalopathy. Am J Neuroradiol 1997;18(5):895-901

Leroy V, Salmi LR, Dupon M, Sentilhes A, Texier-Maugein J, Dequae L, Dabis F, Salamon R, Gecsa. Progression of HIV infection in patients with tuberculosis disease: a cohort study in Bordeaux, France, 1988-1994. Am J Epidemiol 1997;145(3):293-300

Marimoutou C, Chêne G, Dabis F, Lacoste D, Salamon R, Gecsa. L'infection par le VIH et le SIDA en Aquitaine. Dix ans d'expérience d'un système hospitalier, 1985-1995. Presse Med 1997;26(15):703-710

Ortega V, Marimoutou C, Decoin M, Caie J, Dabis F, Salamon R, Gecsa. Les diagnostics récents d'infection à VIH. Données de la Cohorte Aquitaine, 1993-1995. BEH 1997(8):32-33

Rancinan C, Morlat P, Chêne G, Saillour F, Guez S, Lacoste D, Bernard N, Doutre MS, Series C, Aubertin J, Beylot J, Salamon R. Prévalence des manifestations cliniques évocatrices d'allergie au cours de l'infection par le VIH. Etude transversale de 115 sujets. Rev Med Interne 1997;18(9):691-694

Saillour F, Bernard N, Ragnaud JM, Morlat P, Blanchard Y, Monlun E, Labouyrie E, Chêne G, Dabis F, GeCSA. Incidence of cytomegalovirus disease in the Aquitaine Cohort of HIV infected patients: a retrospective survey, 1987-1993. *J Infect* 1997;35(2):155-161

Vimard E, Morlat P, Chêne G, Dumas B, Ragnaud JM, Beylot J, Aubertin J. Intérêt pronostique des nodules cotonneux rétinien chez les patients infectés par le VIH. *Med Mal Infect* 1997;27(5):586-590

1998

Alioum A, Leroy V, Commenges D, Dabis F, Salamon R, GeCSA. Effect of gender, age, transmission category, and antiretroviral therapy on the progression of HIV infection using multi-state Markov models. *Epidemiology* 1998;9(6):605-612

Binquet C, Saillour F, Bernard N, Marimoutou C, Dabis F, GeCSA. Survival of HIV-infected patients with cytomegalovirus retinitis under highly active antiretroviral therapy. *AIDS* 1998;12(18):2502-2504

Bouzigon E, Marimoutou C, Morlat P, Mercié P, Malvy D, Dabis F. Evolution des diagnostics de séropositivité VIH en rapport avec une transmission homosexuelle masculine GECSA-DMI2, Aquitaine, 1985-1997. *BEH* 1998(49):211-213

Chêne G, Binquet C, Moreau JF, Neau D, Pellegrin I, Malvy D, Ceccaldi J, Lacoste D, Dabis F, for the G. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. *AIDS* 1998;12(17):2313-320

Chêne G, Richard V, Morlat P, Trimoulet P, Ragnaud JM, Pellegrin JL, Couzigou P, Dabis F, for the G. Rapid progression of HIV infection in HBeAg-positive patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;19(2):198-199

Couturier E, Schwoebel V, Michon C, Hubert JB, Delmas MC, Morlat P, Boue F, Simonpoli AM, Dabis F, Brunet JB. Determinants of delayed diagnosis of HIV infection in France, 1993-1995. *AIDS* 1998;12(7):795-800

Dupon M, Marimoutou C, Cazorla C, Binquet C, Chêne G, Pellegrin JL, Dutronc H, Nouts C, Dabis F, for the G. Incidence of AIDS-related Kaposi's sarcoma in the Aquitaine Cohort, France, 1988-1996. *Int J Epidemiol* 1998;27(6):1078-1082

Hocke C, Leroy V, Morlat P, Rivel J, Duluc MC, Boulogne N, Tandonnet B, Dupon M, Brun JL, Dabis F, for the G. Cervical dysplasia and HIV infection in women: prevalence and associated factors. *Eur J Obstet Gynecol Reprod Biol* 1998;81(1):69-76

Lacoste D, Dabis F, Boulogne N, Labouyrie E, Merlio JP. Cancer incidence in a cohort of HIV seroconverters. *Cancer* 1998;82(5):996-998

Marimoutou C, Chêne G, Pellegrin I, Moreau JF, Spira R, Neau D, Lacoste D, Ceccaldi J, Malvy D, Dabis F, GeCSA. CD4+ lymphocyte count and plasma HIV-RNA levels in a survey of 1602 HIV-infected patients, Bordeaux, France, 1996-1997. *AIDS* 1998;12(8):962-964

Mignard M, Spira R, Morlat P, Dabis F, Doutre MS, and the G. Correlation of skin disorders with CD4 lymphocyte counts in patients with HIV/AIDS. *J Am Acad Dermatol* 1998;39(2 Part 1):298-299

Morlat P, Chêne G, Vimard E, Dumas B, Ragnaud JM, Beylot J. The presence of cotton-woll spots is predictive for the development of CMV retinitis. *Int J STD AIDS* 1998;9(2):122-123

Saillour F, Bernard N, Dequae-Merchadou L, Marimoutou C, Journot V, Dabis F, Gecsa. Predictive factors of occurrence of cytomegalovirus disease and impact on survival in the Aquitaine Cohort in France, 1985 to 1994. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;17(2):171-178

Spira R, Leroy V, Lacoste D, Salamon R, Dabis F, pour le GECSA. Evolution of case management of patients with HIV infection in France, 1995-1996. *JAMA* 1998;279(4):276

Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F, for the GECSA. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995 to 1997. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;18(4):358-364

Spira R, Mignard M, Doutre MS, Morlat P, Dabis F, Gecsa. Prevalence of cutaneous disorders in a population of HIV-infected patients, South -Western France, 1996. *Arch Dermatol* 1998;134(10):1208-1212

Thiébaud R, Thiessard F, Dequae-Merchadou L, Marimoutou C, Dabis F, Gecsa. Long term follow up of patients under triple therapy is necessary. *BMJ* 1998;317(1762):887-888

1999

Bernard N, Spira R, Ybavez S, Chêne G, Morlat P, Lacoste D, Loury-Lariviere I, Nouts C, Burucoa B, Lebras M, Beylot J. Prevalence and underestimation of pain in HIV-infected patients by physicians: a cross sectional study in a day care hospital. *AIDS* 1999;13(2):293-295

Bonnet F, Dequae-Merchadou L, Taupin JL, Sire S, Dupon M, Ragnaud JM, Lacoste D, Texier-Maugein J, Romagne F, Dabis F, Pellegrin JL, Moreau JF, for the GECSA. Increase in CD3+ CD4- lymphocytes in patients with AIDS and disseminated *Mycobacterium avium-intracellulare* complex infection; a prospective study. *Microbes Infect* 1999;1(10):771-776

Cazorla C, Dabis F, Dupon M, Ragnaud JM, Geniaux M, Pellegrin JL, Salmi LR, et le GECSA. Facteurs associés à la survenue de la maladie de Kaposi chez les patients infectés par le VIH. *Rev Epidemiol Sante Publique* 1999;47(2):109-117

Marimoutou C, Bouzigon E, Mercié P, Morlat P, Malvy D, Dabis F. Evolution des diagnostics de séropositivité VIH en rapport avec une transmission homosexuelle masculine. In: Anrs, editor. *Séropositivité, vie sexuelle et risque de transmission du VIH*. Paris: ANRS; 1999. p. 31-37

Mercié P, Tchamgoue S, Dabis F, Pellegrin JL. Lipodystrophy in HIV-1 infected patients. *Lancet* 1999;354(9181):867-868

Savès M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, Bernard N, Mercié P, Dabis F, Gecsa. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998. *AIDS* 1999;13(17):F115-121

Vandentorren S, Mercié P, Marimoutou C, Dabis F, GeCSA. Evolution des causes de décès des patients infectés par le VIH dans la cohorte aquitaine, 1985-1997. BEH 1999(17):65-66

2000

Binquet C, Saillour F, Bernard N, Rougier MB, Leger F, Bonnal F, Dabis F, for the GECSA. Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine Cohort, 1986-1997. Eur J Epidemiol 2000;16(5):425-432

Cascade European Collaborative Project, Babiker A, Darby S, De Angelis D, Ewart D, Porter K. Time from HIV-1 seroconversion to AIDS and death before widespread use of HAART: a collaborative re-analysis. Lancet 2000;355(9210):1131-1137

Cascade European Collaborative Project, Porter K. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000;355(9210):1158-1159

Huët C, Dabis F, Saillour F, Trimoulet P, Morlat P, Rispal P, Dupon M, De la Taille C, Partisani M, Bertrand M, Ragnaud JM, Couzigou P. Etude multicentrique de la transmission intra-familiale du virus de l'hépatite C dans le contexte de l'infection par le virus de l'immunodéficience humaine. Gastroenterol Clin Biol 2000;24(6-7):611-617

International Collaboration on HIV and Cancer, Appelby P, Beral V, Carpenter L, Casabonne D, Deo H, Langston N, Newton R, Reeves G. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92(22):1823-1830

Morlat P, Marimoutou C, Dequae-Merchadou L, Pellegrin I, Mercié P, Neau D, Beylot J, Dabis F, for the GECSA. Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996-1998. J Acquir Immune Defic Syndr 2000;23(3):255-260

Porter K, Babiker A, Walker AS, Darbyshire J, Gill N, Cascade Collaboration. Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time observational studies; results from CASCADE. AIDS 2000;14(13):1899-1906

Porter K, Babiker A, Walker AS, Darbyshire J, Gill N, Cascade Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000;1(4):224-231

Thiébaud R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercié P, Daucourt V, for the GECSA. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. J Acquir Immune Defic Syndr 2000;23(3):261-265

Thiébaud R, Daucourt V, Mercié P, Ekouevi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, Dabis F, GeCSA. Lipodystrophy, metabolic disorders, and HIV infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000;31(6):482-487

Thiébaud R, Malvy D, Marimoutou C, Dabis F, GeCSA. Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997. Eur J Epidemiol 2000;16(7):633-639

Thiébaud R, Morlat P, Jacqmin-Gadda H, Neau D, Mercié P, Dabis F, Chêne G, and the GECSA. Clinical progression of HIV-1 infected patients according to the viral response during the first year of antiretroviral treatment. *AIDS* 2000;14(8):971-978

Thiessard F, Morlat P, Marimoutou C, Labouyrie E, Ragnaud JM, Pellegrin JL, Dupon M, Dabis F, for the GECSA. Prognostic factors after non-hodgkin lymphoma in patients infected with HIV: Aquitaine Cohort, France, 1986-1997. *Cancer* 2000;88(7):1696-1702

2001

Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker AS, Cascade Collaboration. Is the Time From HIV Seroconversion a Determinant of the Risk of AIDS After Adjustment for Updated CD4 Cell Counts? *J Acquir Immune Defic Syndr* 2001;28(2):158-165

Binquet C, Chêne G, Jacqmin-Gadda H, Journot V, Savès M, Lacoste D, Dabis F, Gecsa. Modeling changes in CD4+ lymphocyte counts after starting HAART and the relationship with the risk of opportunistic infections, Aquitaine Cohort, 1996-1997. *Am J Epidemiol* 2001;153(4):386-393

Cascade European Collaborative Project. The relationships between the HIV test interval, demographic factors and HIV disease progression. *Epidemiol Infect* 2001;127(1):91-100

Malvy D, Thiébaud R, Marimoutou C, Dabis F, for the GECSA. Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults. Aquitaine cohort, France, 1985-1997. *J Am Coll Nutr* 2001;20(6):609-615

Marimoutou C, Chêne G, Mercié P, Neau D, Farbos S, Morlat P, Ceccaldi J, Dabis F. Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. *J Acquir Immune Defic Syndr* 2001;27(2):161-167

Nouts C, Bonarek M, Morlat P, Delevaux I, Bonnet F, Lacoste D, Bernard N, Beylot J. The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir. *Int J STD AIDS* 2001;12(1):29-33

Savès M, Morlat P, Chêne G, Peuchant E, Pellegrin I, Bonnet F, Bernard N, Lacoste D, Salamon R, Beylot J. Prognostic value of plasma markers of immune activation in patients with advanced hiv disease treated by combination antiretroviral therapy. *Clin Immunol* 2001;99(3):347-352

Thiébaud R, Dequae-Merchadou L, Ekouevi DK, Mercié P, Malvy D, Neau D, Dabis F, Gecsa. Incidence and risk factors of severe hypertriglyceridemia in the era of HAART. Aquitaine Cohort, France, 1996-1999. *HIV Med* 2001;2(2):84-88

Vandentorren S, Mercié P, Marimoutou C, Neau D, Malvy D, Farbos S, Dabis F. Trends in causes of death in the Aquitaine Cohort of HIV infected patients, 1995-1997. *Eur J Epidemiol* 2001;17(1):7-10

Yazdanpanah Y, Chêne G, Losina E, Goldie SJ, Dequae-Merchadou L, Alfandari S, Seage GR, Sullivan L, Marimoutou C, Paltiel AD, Salamon R, Mouton Y, Freedberg KA. Incidence of primary opportunistic infections in two HIV-infected French clinical cohorts. *Int J Epidemiol* 2001;30(4):864-871

2002

Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker AS, Cascade Collaboration. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. *Int J Epidemiol* 2002;31(5):951-958

Bonnet F, Bonarek M, Abrij A, Beylot J, Morlat P. Metabolic acidosis in HIV-infected patients. *Clin Infect Dis* 2002;34(9):1289-1290

Bonnet F, Lawson-Ayayi S, Thiébaut R, Ramanampamonjy R, Lacoste D, Bernard N, Malvy D, Bonarek M, Djossou F, Beylot J, Dabis F, Morlat P, GeCSA. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. *Clin Infect Dis* 2002;35(10):1231-1237

Bonnet F, Morlat P, Chêne G, Mercié P, Neau D, Chossat I, Decoin M, Djossou F, Beylot J, Dabis F, GECSA. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. *HIV Med* 2002;3(3):195-199

Bonnet F, Savès M, Morlat P, Droz C, Chêne G, Peuchant E, Bernard N, Lacoste D, Salamon R, Beylot J. Correlations of soluble interleukin-2 and tumor necrosis factor type II receptors with immunologic and virologic responses under HAART. *J Clin Immunol* 2002;22(2):75-82

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360(9327):119-129

Lewden C, Bonnet F, Belivacqua S, Heripret L, Mat T, P M, Jouglu E, Dabis F, Chêne G, Salmon D, GeCSA, Mortalité. Causes de décès chez les usagers de drogues français infectés par le VIH, 1995-2000. *Ann Med Interne* 2002;153(7 Suppl):2S4-2S10

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H, GeCSA. Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced Patients. *Antimicrob Agents Chemother* 2002;46(9):2926-2932

Mercié P, Thiébaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Morlat P, Ragnaud JM, Dupon M, Malvy D, Bellet H, Lawson-Ayayi S, Roudaut R, Dabis F. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. *Ann Med* 2002;34(1):55-63

Rancinan C, Neau D, Savès M, Lawson-Ayayi S, Bonnet F, Mercié P, Dupon M, Couzigou P, Dabis F, Chêne G, GeCSA. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? *AIDS* 2002;16(10):1357-1362

van Benthem BH, Vernazza P, Coutinho RA, Prins M, for the European Study on the Natural History of HIV Infection in Women, the Swiss HIV Cohort Study. The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women. *AIDS* 2002;16(6):919-924

2003

Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker AS, Cascade Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. *Lancet* 2003;362(9392):1267-1274

Babiker A, Darbyshire J, Pezzotti P, Porter K, Prins M, Sabin C, Walker AS, Cascade Collaboration. Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. *J Acquir Immune Defic Syndr* 2003;32(3):303-310

Babiker A, Darbyshire J, Pezzotti P, Porter K, Prins M, Sabin C, Walker AS, Cascade Collaboration. Impact of Tuberculosis on HIV Disease Progression in Persons With Well-Documented Time of HIV Seroconversion. *J Acquir Immune Defic Syndr* 2003;32(2):184-190

Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. *Lancet* 2003;361(9359):726-735

Carr A, Law M, HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. *J Acquir Immune Defic Syndr* 2003;33(5):571-576

Chêne G, Sterne JAC, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, deWolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME, ART Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. *Lancet* 2003;362(9385):679-686

Clements M, Law M, Pedersen C, Kaldor J, Collaboration C. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. *HIV Med* 2003;4(4):332-337

Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group, Friis-Møller N, Sabin C, Weber R, d'Arminio Monforte A, El-Sadr W, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law M, Kirk O, Phillips AN, Lundgren J. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. *N Engl J Med* 2003;349(21):1993-2003

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, Law MG, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, for the DAD Study Group. Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. *AIDS* 2003;17(8):1179-1193

Ioannidis JPA, Trikalinos TA, Law M, Carr A, for the HIV Lipodystrophy Case Definition Study Group. HIV lipodystrophy case definition using artificial neural network modelling. *Antivir Ther* 2003;8(5):435-441

Law M, Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD, Group DADS. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. *HIV Med* 2003;4(1):1-10

Thiébaud R, Chêne G, Jacqmin-Gadda H, Morlat P, Mercié P, Dupon M, Neau D, Ramaroson H, Dabis F, Salamon R, Gecsa. Time-Updated CD4+ T Lymphocyte Count and HIV RNA as Major Markers of Disease Progression in Naive HIV-1-Infected Patients Treated With a Highly Active Antiretroviral Therapy: The Aquitaine Cohort, 1996-2001. *J Acquir Immune Defic Syndr* 2003;33(3):380-386

Thiébaud R, Savès M, Mercié P, Cipriano C, Chêne G, Dabis F. Epidémiologie du risque vasculaire d'origine athéroscléreuse chez les patients infectés par le VIH-1. *Presse Med* 2003;32(30):1419-1426

Touloumi G, Pantazis N, Babiker A, Walker AS, Katsarou O, Hatzakis A, Karafoulidou A, Porter K, Darbyshire J, CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. *J Acquir Immune Defic Syndr* 2003;34(1):76-83

2004

Bonnet F, Balestre E, Thiébaud R, Mercié P, Dupon M, Morlat P, Dabis F. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. *HIV Med* 2004;5(3):133-139

Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. *Antivir Ther* 2004;9(5):787-800

Cascade Collaboration, Bhaskaran K, Brettle R, Porter K, Walker AS. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. *AIDS* 2004;18(4):673-681

Cascade Collaboration, Phillips AN, Pezzotti P. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. *AIDS* 2004;18(1):51-58

Collaboration of HIV Cohorts, Phillips AN, Ledergerber B, Lundgren J, Hogg B, d'Arminio Monforte A, Castelli F, Walker AS, Staszewski S, Thiébaud R, Gazzard BG, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D. Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound. *J Infect Dis* 2004;190(4):675-687

d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Møller N, Writing Committee of the DAD Study Group. Cardio- and cerebrovascular events in HIV-infected persons. *AIDS* 2004;18(13):1811-1817

d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J. Changing incidence of central nervous system diseases in the EuroSIDA cohort. *Ann Neurol* 2004;55(3):320-328

Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, Mercey D, Machala L, Horban A, Lundgren JD. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. *J Infect Dis* 2004;190(1):148-155

Fontas E, Van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, D'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, De Wit S, Lundgren JD, Pradier C, Reiss P, D. A. D. Study Group. Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles? *J Infect Dis* 2004;189(6):1056-1074

Kirk O, Mocroft A, Lundgren JD. [Decline in AIDS and death rates in the EuroSIDA study. An observational study]. *Ugeskr Laeger* 2004;166(26-31):2572-2576

Martin K, Lawson-Ayayi S, Miremont-Salamé G, Blaizeau MJ, Balestre E, Lacoste D, Ragnaud JM, Malvy D, Dupon M, Mercié P, Schaefferbeke T, Haramburu F, Dabis F. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002). *HIV Med* 2004;5(6):421-426

Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J, EuroSIDA study group. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. *AIDS* 2004;18(17):2333-2337

Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. *Cancer* 2004;100(12):2644-2654

Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. *J Infect Dis* 2004;190(11):1947-1956

Mocroft A, Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, Blaxhult A, Mulcahy F, Gatell JM, Lundgren JD. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. *HIV Med* 2004;5(6):437-447

Neau D, Winnock M, Galperine T, Jouvencel A, Castera L, Legrand E, Tranchant E, Balestre E, Lacoste D, Ragnaud J, Dupon M, Lafon M, Dabis F, Gecsa. Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. *HIV Med* 2004;5(3):171-173

Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulcahy F, Fisher M, Machala L, Lundgren JD, EuroSIDA study Group. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. *AIDS* 2004;18(13):1795-804

Thiébaud R, Jacqmin-Gadda H. Modélisation longitudinale de données incomplètes : exemple de la charge virale plasmatique du VIH. *Journal de la Société Française de Statistiques* 2004;145(2):33-47

Yust I, Fox Z, Burke M, Johnson A, Turner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. *Eur J Clin Microbiol Infect Dis* 2004;23(7):550-559

2005

Alioum A, Commenges D, Thiébaut R, Dabis F, Gecsa. A multistate approach for estimating the incidence of human immunodeficiency virus by using data from a prevalent cohort study. *Appl Statist* 2005;54(4):739-752

Antiretroviral Therapy Cohort Collaboration, d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. *Arch Intern Med* 2005;165(4):416-423

Antiretroviral Therapy Cohort Collaboration, Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fatkenheuer G, Sterne JA. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. *Clin Infect Dis* 2005;41(12):1772-1782

Bonnet F, Balestre E, Bernardin E, Pellegrin JL, Neau D, Dabis F. Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999--2003. *Antivir Chem Chemother* 2005;16(1):63-67

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, GECSA. Determinants of clinical progression in antiretroviral-naïve HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. *HIV Med* 2005;6(3):198-205

Carter M. EuroSIDA cohort: 9% coinfectd with HIV/HBV. *IAPAC Mon* 2005;11(4):110

Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD, EuroSIDA study group. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. *Antivir Ther* 2005;10(7):791-802

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. *AIDS* 2005;19(6):593-601

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, O K, Lundgren JD, EuroSIDA study group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. *AIDS* 2005;19(6):593-601

Lawson-Ayayi S, Bonnet F, Bernardin E, Ragnaud JM, Lacoste D, Malvy D, Blaizeau MJ, Miremont-Salame G, Dupon M, Mercié P, Dabis F. A vascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France. *Clin Infect Dis* 2005;40(8):1188-1193

Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jorgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kucherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, K P, Cascade Collaboration. Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003. *J Acquir Immune Defic Syndr* 2005;40(5):505-511

May M, Porter K, Sterne JA, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. *J Clin Epidemiol* 2005;58(10):1033-1041

Mercié P, Thiébaud R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Cipriano C, Neau D, Morlat P, Ragnaud JM, Dupon M, Bonnet F, Lawson Ayayi S, Malvy D, Roudaut R, Dabis F, Gecsa. Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. *HIV Med* 2005;6:380-387

Mocroft A, Oancea C, van Lunzen J, Vanhems P, Banhegyi D, Chiesi A, Vinogradova E, Maayan S, Phillips AN, Lundgren J, EuroSIDA study group. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. *Am J Gastroenterol* 2005;100(7):1446-1454

Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? *Antivir Ther* 2005;10(7):779-790

Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JD, EuroSIDA study group. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? *AIDS* 2005;19(18):2117-2125

Neau D, Winnock M, Jouvencel AC, Faure M, Castera L, Legrand E, Lacoste D, Ragnaud JM, Dupon M, Fleury H, Lafon ME, Dabis F. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. *Clin Infect Dis* 2005;40(5):750-753

Pellegrin I, Thiébaud R, Blanco P, Viallard JF, Schrive MH, Merel P, Chêne G, Fleury H, Moreau JF, Pellegrin JL. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. *J Med Virol* 2005;77(2):164-172

Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis* 2005;192(6):992-1002

Sabin C, on behalf of the Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? *AIDS* 2005;19(17):1995-2000

Thiébaud R, Aurillac-Lavignolle V, Bonnet F, Ibrahimd N, Cipriano C, Neau D, Dupon M, Dabis F, Mercié P, Gecsa. Change in atherosclerosis progression in HIV infected patients: ANRS Aquitaine Cohort, 1999-2004. *AIDS* 2005;19(7):729-731

Thiébaud R, El-Sadr WM, Friis-Moller N, Rickenbach M, Reiss P, d'Arminio Monforte A, Morfeldt L, Fontas E, Kirk O, De Wit S, Calvo G, Law MG, Dabis F, Sabin CA, Lundgren JD. Predictors of hypertension and changes of blood pressure in HIV-infected patients. *Antivir Ther* 2005;10(7):811-823

Thiébaud R, Jacqmin-Gadda H, Babiker A, Commenges D, Cascade Collaboration. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4⁺ cell count and HIV RNA viral load in response to treatment of HIV infection. *Stat Med* 2005;24(1):65-82

Thiébaud R, Pellegrin I, Chêne G, Viallard JF, Fleury H, Moreau JF, Pellegrin JL, Blanco P. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 x 10⁶ cells/l. *AIDS* 2005;19(1):53-61

2006

Antiretroviral Therapy Cohort Collaboration, Hogg RS, May M, Phillips AN, Costagliola D, Sterne J, Sabin C, de Wolf F, Ledergerber B, D'Arminio Monforte A, Justice AC, Gill J, Fusco G, Staszewski S, Rockstroh J, Chêne G, Egger M. Rates of disease progression according to initial HAART regimen. A collaborative analysis of 12 prospective studies. *J Infect Dis* 2006;194(5):612-622

Antiretroviral Therapy Cohort Collaboration, May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fatkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. *Lancet* 2006;368(9534):451-458

Balestre E, Dupon M, Capdepon S, Thiébaud R, Boucher S, Fleury H, Dabis F, Masquelier B, Gecsa. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. *J Clin Virol* 2006;36(2):95-99

Bannister WP, Kirk O, Gatell JM, Knysz B, Viard JP, Mens H, Monforte AD, Phillips AN, Mocroft A, Lundgren JD, EuroSIDA study group. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. *J Acquir Immune Defic Syndr* 2006;42(2):229-237

Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A. EuroSIDA study group. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. *Antivir Ther* 2006;11(6):707-715

Benard A, Tessier JF, Rambeloarisoa J, Bonnet F, Fossoux H, Neau D, Dutronc H, Lazaro E, Dabis F, Chêne G. HIV infection and tobacco smoking behaviour: prospects for prevention? ANRS CO3 Aquitaine Cohort, 2002. *Int J Tuberc Lung Dis* 2006;10(4):378-383

Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, S J, van der Hoek L, Cascade collaboration. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4⁺ T-cell count and HIV-1 RNA load. *Antivir Ther* 2006;11(2):173-178

Bonnet F, Balestre E, Thiébaut R, Morlat P, Pellegrin JL, Neau D, Dabis F, GeCSA. Factors Associated with the Occurrence of AIDS-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy: Aquitaine Cohort, France. *Clin Infect Dis* 2006;42(3):411-417

Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M, Antiretroviral Therapy in Lower Income Countries C, Antiretroviral Therapy in Lower Income Countries Collaboration, ART Cohort Collaboration groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 2006;367(9513):817-824

Capdepon S, Aurillac-Lavignolle V, Faure M, Dupon M, Morlat P, Ragnaud JM, Chêne G, Fleury H, Masquelier B, GeCSA. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients. *J Clin Virol* 2006;36(1):36-42

Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. *HIV Med* 2006;7(4):218-230

Lazaro E, Coureau G, Guedj J, Bianco P, Pellegrin I, Commenges D, Dabis F, Moreau JF, Pellegrin JL, Thiébaut R, ANRS Co3 Aquitaine Cohort. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of *Mycobacterium avium* complex infection. *Antivir Ther* 2006;11(3):343-350

Mocroft A, Horban A, Clumeck N, Stellbrink HJ, Montforte AD, Zilmer K, Kirk O, Gatell J, Phillip A, Lundgren DJ, EuroSIDA study Group. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000. *HIV Clin Trials* 2006;7(6):271-284

Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren JD, EuroSIDA study Group. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. *Clin Trials* 2006;3(2):119-132

Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A, Phillips AN, Lundgren JD, EuroSIDA study Group. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. *Scand J Infect Dis* 2006;38(11-12):1092-1097

Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kucherer C, Poggensee G, Gill J, Porter K, Cascade Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. *AIDS* 2006;20(1):21-28

Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. *J Infect Dis* 2006;194(5):633-641

Puoti M, Cozzi-Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, d'Arminio Monforte A, HBV-HIV International Intercohort Study Group. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. *Antivir Ther* 2006;11(5):567-574

Rockstroh JK. Influence of viral hepatitis on HIV infection. *J Hepatol* 2006;44(1 Suppl):S25-S27

Thiébaud R, Jacqmin-Gadda H, Walker S, Sabin C, Prins M, Del Amo J, Porter K, Dabis F, Chêne G. Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion. *HIV Med* 2006;7(1):1-9

Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, d'Arminio Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med* 2006;166(15):1632-1641

Winnock M, Neau D, Castera L, Viot J, Lacoste D, Pellegrin JL, Dupon M, Jutand MA, Colombani F, Dabis F, Gecsa. Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. *Gastroenterol Clin Biol* 2006;30(2):189-195

2007

Antiretroviral Therapy Cohort Collaboration, May M, Sterne J, Sabin C, Costagliola D, Justice A, Thiébaud R, Gill J, Phillips AN, Reiss P, Hogg B, Ledergerber B, d'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. *AIDS* 2007;21(9):1185-1197

Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, Ragnaud JM, Viallard JF, Dabis F, Chêne G. Tobacco addiction and HIV infection: toward the implementation of cessation programs. *ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS* 2007;21(7):458-468

Bonnet F, Aurillac-Lavignolle V, Breilh D, Thiébaud R, Peuchant E, Bernard N, Lacoste D, Dabis F, Beylot J, Chêne G, Morlat P. Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. *HIV Clin Trials* 2007;8(1):53-60 Bonnet F, Chêne G, Thiébaud R, Dupon M, Lawson Ayayi S, Pellegrin JL, Dabis F, Morlat P, Gecsa. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. *HIV Med* 2007;8:547-554

Brinkhof MW, Egger M, Bouille A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Meda JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borgh S, Schechter M, Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA), ART Cohort Collaboration. Tuberculosis following initiation of antiretroviral therapy in low-income and high-income countries. *Clin Infect Dis* 2007;45(1):1518-1524

Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F, GECSA, Australian HIV Observational Database, St Vincent's Hospital Cohort study group. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. *HIV Med* 2007;8(3):171-180

Castera L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock M, Dabis F, Neau D. Hepatic steatosis in HIV-HCV coinfectd patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. *Aliment Pharmacol Ther* 2007;26(11-12):1489-1498

Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, Mocroft A, Phillips AN, Olsen CH, Gatell JM, Gunthard HF, Reiss P, Perno CF, Clotet B, Lundgren JD, EuroSIDA study group. Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. *J Infect Dis* 2007;196(8):1180-1190

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD, EuroSIDA study group. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. *AIDS* 2007;21(6):721-732

D. A. D. Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr W, Thiébaut R, De Wit S, O K, Fontas E, Law MG, Phillips A, Lundgren JD. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. *N Engl J Med* 2007;356(17):1723-1735

Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber J, Cascade Collaboration. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. *AIDS* 2007;21(10):1283-1291

Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD, EuroSIDA study group. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. *AIDS* 2007;21(15):2033-2042

Hill A, Grossman H, Cohen C, Nadler J, Peeters M. Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial. *HIV Clin Trials* 2007;8(2):68-76

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. *HIV Med* 2007;8(2):96-104

Kowalska JD, Mocroft A, Blaxhult A, Colebunders R, van Lunzen J, Podlekareva D, Hansen AB, Machala L, Yust I, Benfield T, EuroSIDA study group. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. *AIDS Res Hum Retroviruses* 2007;23(10):1183-1188

Lewden C, Chêne G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C, ANRS CO8 APROCO-COPILOTE Study Group, ANRS CO3 AQUITAINE

Study Group. HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm³ on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population. *J Acquir Immune Defic Syndr* 2007;46(1):72-77

Masquelier B, Capdepon S, Neau D, Peuchant O, Taupin JL, Coakley E, Lie Y, Carpentier W, Dabis F, Fleury HJ, ANRS CO3 Aquitaine Cohort. Virological characterization of an infection with a dual-tropic, multidrug-resistant HIV-1 and further evolution on antiretroviral therapy. *AIDS* 2007;21(1):103-106

Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD, EuroSida Study Group. Chronic renal failure among HIV-1-infected patients. *AIDS* 2007;21(9):1119-1127

Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD, EuroSida Study Group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. *Lancet* 2007;370(9585):407-413

Neau D, Winnock M, Castera L, Bail BL, Loko MA, Geraut L, Dupon M, Ragnaud JM, Lacoste D, Lafon ME, Bioulac-Sage P, Dabis F, Geasa. Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. *J Acquir Immune Defic Syndr* 2007;45(2):168-173

Pellegrin I, Breilh D, Coureau G, Boucher S, Neau D, Merel P, Lacoste D, Fleury H, Saux MC, Pellegrin JL, Dabis F, Thiébaut R. Interpretation of Genotype and Pharmacokinetics for Resistance to Fosamprenavir/ritonavir-Based Regimens in Antiretroviral-Experienced Patients (Zephir Study). *Antimicrob Agents Chemother* 2007;51(4):1473-1480

Peuchant O, Capdepon S, Ragnaud JM, Aurillac Lavignolle V, Thiébaut R, Fleury H, Masquelier B. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naïve patients from the ANRS Aquitaine Cohort. *Antivir Ther* 2007;12(4):559-562

Sterne J, May M, Sabin C, Phillips A, Costagliola D, Chêne G, Justice A, de Wolf F, Hogg B, Battegay M, D'Arminio Monforte A, Fätkenheuer G, Staszewski S, Gill J, Egger M, Antiretroviral Therapy Cohort Collaboration. Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy. Collaborative Analysis of Cohorts of HIV-1-Infected Patients. *J Acquir Immune Defic Syndr* 2007;46(5):607-615

Trimoulet P, Boutonnet M, Winnock M, Faure M, Loko MA, De Ledinghen V, Bernard PH, Castera L, Foucher J, Dupon M, Ragnaud JM, Lafon ME, Couzigou P, Dabis F, Fleury H, Neau

D. Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004. *Gastroenterol Clin Biol* 2007;31:1088-1094

Worm SW, de Wit S, Weber J, Sabin C, Reiss P, El Sadr W, Montforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren J, Friis-Møller N, D. A. D. Study Group. Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? *Antivir Ther* 2007;12(Suppl 2):L10

2008

Badiou S, Thiébaud R, Aurillac-Lavignolle V, Dabis F, F L, Cristol JP, Mercié P, Gecsa. Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. *J Infect* 2008;57(1):47-54

Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. *J Acquir Immune Defic Syndr* 2008;48(3):324-333

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. *AIDS* 2008;22(3):367-376

Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K, Cascade Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. *JAMA* 2008;300(1):51-59

Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucchi M, Sabin C, Phillips A, Porter K. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. *Ann Neurol* 2008;63(2):213-221

Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehse N, Mercié P, Morlat P, Thiébaud R, Dabis F, Gecsa. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors, ANRS CO3 Aquitaine cohort. *AIDS* 2008;22(3):395-402

Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD, EuroSIDA study group. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. *AIDS* 2008;22(16):2187-2198

D. A. D. Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. *AIDS* 2008;22(14):F17-F24

D'Arminio Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. *AIDS* 2008;22(16):2143-2153

De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips A. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *Diabetes Care* 2008;31(6):1224-1229

Drylewicz J, Matheron S, Lazaro E, Damon D, Bonnet F, Simon F, Dabis F, Brun-Vezinet F, Chêne G, Thiébaud R. Comparison of Viro-Immunologic Markers Evolution between HIV-1 and HIV-2 Infected Patients in France from the ANRS CO 3 Aquitaine and CO 5 HIV-2 cohorts. *AIDS* 2008;22(4):457-468

Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K, Collaboration C. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. *J Infect Dis* 2008;197(3):398-404

Fessel J, Hurley LB. Incidence of pancreatitis in HIV-infected patients: comment on findings in EuroSIDA cohort. *AIDS* 2008;22(1):145-147

Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A. Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). *Open AIDS J* 2008;2:3-9

Harris RJ, Sterne J, Abgrall S, Dabis F, Reiss P, Saag M, Phillips A, Chêne G, Gill J, Justice A, Rockstroh J, Sabin C, Mocroft A, Bucher HC, Hogg RS, D'Arminio Monforte A, May M, Egger M, Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. *Antivir Ther* 2008;13(8):959-967

Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M, Antiretroviral Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 2008;372(9635):293-299

Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernandez-Aguado I, Meyer L, Porter K, del Amo J, Cascade Collaboration. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. *Am J Epidemiol* 2008;168(5):532-540

Lewden C, Chene G, Morlat P, Raffi F, Dabis F, Leport C. Mortalité des adultes infectés par le VIH comparée à la population générale : données à long terme et selon les lymphocytes CD4. *Med Sci (Paris)* 2008;24(10):804-806

Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, Jougla E, Semaille C, Morlat P, Salmon D, Cacoub P, Chêne G. Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The "Mortalite 2000 and 2005" Surveys (ANRS EN19 and Mortavic). *J Acquir Immune Defic Syndr* 2008;48:590-598

Loko MA, Castera L, Dabis F, Le Bail B, Winnock M, Coureau G, Bioulac Sage P, de Ledinghen V, Neau D, Gecea. Validation and comparison of simple non invasive indexes for predicting liver fibrosis in HIV-HCV coinfectd patients: ANRS CO3 Aquitaine cohort. *Am J Gastroenterol* 2008;103(8):1973-1980

Mocroft A, Horban A, Clotet B, d'Arminio Monforte A, Bogner JR, Aldins P, Staub T, Antunes F, Katlama C, Lundgren JD. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. *HIV Med* 2008;9(1):41-46

Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD. Loss to follow-up in an international, multicentre observational study. *HIV Med* 2008;9(5):261-269

Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Gunthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miro JM, Staszewski S, Sterne JA, Art-CC. Does Short-term Virologic Failure Translate to Clinical Events in ARV-naïve Patients Initiating ART in Clinical Practice? *AIDS* 2008;22(18):2481-2492

Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K, Cascade Collaboration. The effect of antiretroviral treatment of different durations in primary HIV infection. *AIDS* 2008;22(18):2441-2450

Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiebaut R, Breilh D. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA Study). *Antivir Ther* 2008;13(2):271-279

Peuchant O, Thiébaut R, Capdepon S, Lavignolle-Aurillac V, Neau D, Morlat P, Dabis F, Fleury H, Masquelier B, Anrs Co3 Aquitaine Cohort. Transmission of HIV-1 minority resistant variants and response to first-line antiretroviral therapy. *AIDS* 2008;22(12):1417-1423

Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O. The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. *Cent Eur J Public Health* 2008;16(3):99-105

Reekie J, Mocroft A, Kirk O, Lundgren DJ. The clinical application of the EuroSIDA risk score. *AIDS & Hepatitis Digest* 2008;126:1-5

Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? *AIDS* 2008;22(17):2381-2390

Sabin C, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chêne G, Lundgren J, COHERE. Response to combination antiretroviral therapy: variation by age. *AIDS* 2008;22(12):1463-1472

Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD, DAD Study group. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. *Clin Infect Dis* 2008;46(7):1101-1110

Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Moller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD, DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet* 2008;371(9622):1417-1426

Smith CJ, Mocroft A, Lundgren JD. Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. *AIDS* 2008;22(8):997-998

Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. *J Infect Dis* 2008;198(9):1337-1344

Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, Porter K, CASCADE Collaboration. Rates and Determinants of Virologic and Immunological Response to HAART Resumption After Treatment Interruption in HIV-1 Clinical Practice. *J Acquir Immune Defic Syndr* 2008;49(5):492-498

2009

Antiretroviral Therapy Cohort Collaboration, Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS* 2009;23(16):2199-208

Antiretroviral Therapy Cohort Collaboration, Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fätkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. *Clin Infect Dis* 2009;48(8):1138-1151

Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris DR, May M, Hogg B, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, Von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. *Int J Epidemiol* 2009;38(6):1624-1633

Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NKT, Bruun Jorgensen L, de Mendoza C, Bhaskaran K, Gill ON, Johnson AL, Pillay D, Cascade Collaboration. Phylogenetic Reconstruction of Transmission Events from Individuals with Acute HIV Infection: Toward More-Rigorous Epidemiological Definitions. *J Infect Dis* 2009;199(3):427-431

Bruyand M, Thiébaud R, Lawson Ayayi S, Joly P, Sasco AJ, Mercié P, Pellegrin JL, Neau D, Dabis F, Morlat P, Chêne G, Bonnet F, Gecsa. Role of uncontrolled HIV RNA and immunodeficiency in the occurrence of malignancy in HIVinfected patients in the cART era, ANRS CO3 Aquitaine Cohort. *Clin Infect Dis* 2009;49(7):1109-1116

COHERE, Collaboration of Observational HIV Epidemiological Research Europe study group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro J, Lundgren DJ, Chêne G, Egger M. Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study. *Antivir Ther* 2009;14(8):1065-1074

COHERE, Collaboration of Observational HIV Epidemiological Research Europe study group, Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chêne G, Lundgren J, Egger M. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. *AIDS* 2009;23(15):2029-2037

Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucchi M, Hamouda O, Prins M, Walker AS, Porter K, Sabin C, Chêne G, Cascade Collaboration. Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. *CASCADE*, 1996-2006. *AIDS* 2009;23(13):1743-1753

Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczar D, Fatkenheuer G, Staszewski S, Gill J, Sterne JA, ART-CC. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. *J Acquir Immune Defic Syndr* 2009;52(3):357-363

Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. *J Acquir Immune Defic Syndr* 2009;50(5):457-463

Recordon-Pinson P, Anies G, Bruyand M, Neau D, Morlat P, Pellegrin JL, Groppi A, Thiebaut R, Dabis F, Fleury H, Masquelier B, Anrs Co3 Aquitaine Cohort. HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity. *Antivir Ther* 2009;14(4):551-556

van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. *Antivir Ther* 2009;14(1):75-83

When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Gekus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, d'Arminio Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole SR, Brodt HR, Casabona J, Chêne G, del Amo J, Guest J, Kitahata M, Lampe F, Mocroft A, Reiss P. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 2009;373(9672):1352-1363

Wittkop L, Breilh D, da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. *J Antimicrob Chemother* 2009;63(6):1251-1255

Worm SW, de Wit S, Weber R, Sabin C, Reiss P, El-Sadr W, D'Arminio Monforte A, Kirk O, Fontas E, Dabis F, Law M, Lundgren DJ, Friis-Møller N. Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD Study). *Circulation* 2009;119(6):805-811

Worm SW, Sabin C, Reiss P, El-Sadr W, d'Arminio Monforte A, Pradier C, Thiébaut R, Law M, Rickenbach M, De Wit S, Lundgren DJ, Moller NF. Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) than the sum of its components in HIV-infected individuals. Data Collection on Adverse Events of Anti-HIV Drugs (The DAD study). *Diabetes Care* 2009;32(3):474-480

Young J, Bucher HC, Guenthard HF, Rickenbach M, Fux CA, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Battegay M. Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. *Antivir Ther* 2009;14(6):771-9

2010

Antiretroviral Therapy Cohort Collaboration, Gill J, May M, Lewden C, Saag M, Mugavero M, Reiss P, Ledergerber B, Mocroft A, Harris R, Fux CA, Justice A, Costagliola D, Casabona J, Hogg RS, Khaykin P, Lampe F, Vehreschild J, Sterne JA, Egger M, Brodt HR, Chêne G, Dabis F, Monforte AD, de Wolf F, Fatkenheuer G, Guest J, Kirk O, Kitahata M, Sterling T. Causes of Death in HIV1-Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies. *Clin Infect Dis* 2010;50(10):1387-1396

Benard A, Mercie P, Alioum A, Bonnet F, Lazaro E, Dupon M, Neau D, Dabis F, Chene G. Bacterial Pneumonia among HIV-Infected Patients: Decreased Risk After Tobacco Smoking Cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. *PLoS One* 2010;5(1):e8896

COHERE, Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H. Is it safe to discontinue primary *Pneumocystis jirovecii* pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? *Clin Infect Dis* 2010;51(5):611-619

Data Collection on Adverse Events of Anti HIV Drugs Study Group, Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J. HBV or HCV co-infections and risk of myocardial infarction in HIV-infected individuals: The D:A:D Cohort Study. *Antivir Ther* 2010;15(8):1077-1086

Deti EK, Thiebaut R, Bonnet F, Lawson Ayayi S, Dupon M, Neau D, Pellegrin JL, Malvy D, Tchamgoue S, Dabis F, Morlat P, GeCSA. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS CO3 Aquitaine Cohort, France. *HIV Med* 2010;11(5):308-317

Encrenaz G, Benard A, Rondeau V, Bonnet F, Lazaro E, Neau D, Dupon M, Dabis F, Mercie P, Chêne G, Group ACAS, GeCSA. Determinants of Smoking Cessation Attempts among HIV-Infected Patients Results from a Hospital-Based Prospective Cohort. *Curr HIV Res* 2010;8(3):212-217

Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. *Eur J Cardiovasc Prev Rehabil* 2010;17(5):491-501

Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K, Cascade Collaboration. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. *AIDS* 2010;24(17):2697-2704

Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucchi M, Ledergerber B, Mocroft A, Podzamczar D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, Garcia F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warszawski J, Thorne C, Masip J, Perez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Gunthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chêne G, Lundgren JD, Phillips AN. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. *Arch Intern Med* 2010;170(5):410-419

Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. *AIDS* 2010;24(11):1667-1678

Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. *Antivir Ther* 2010;15(4):563-570

Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. *J Acquir Immune Defic Syndr* 2010;55(2):262-70

Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. *HIV Med* 2010;11(7):469-478

Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte A, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS* 2010;24(10):1537-1548

Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte A, Flisiak R, Lundgren J. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. *J Antimicrob Chemother* 2010;65(3):548-555

Trullas JC, Mocroft A, Cofan F, Turret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miro JME. Dialysis and renal transplantation in HIV-infected patients: a European survey. *J Acquir Immune Defic Syndr* 2010;55(5):582-589

Wolbers M, Babiker A, Sabin C, Young J, Dorrucchi M, Chene G, Mussini C, Porter K, Bucher HC. Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy-The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. *PLoS Med* 2010;7(2):e1000239

Worm SW, Friis-Moller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C, Dad. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. *AIDS* 2010;24(3):427-435

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Montforte AD, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren DJ, Dad. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis* 2010;201(3):318-330

2011

Bailey H, Townsend C, Cortina-Borja M, Thorne C, European Collaborative Study in EuroCoord. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. *Antivir Ther* 2011;16(6):895-903

Bannister WP, Cozzi-Lepri A, Kjaer J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. *J Antimicrob Chemother* 2011;66(4):901-11

Bruyand M, Broussy S, Reigadas S, Vanhenhede MA, Tchamgoue S, Bonnal F, Dauchy F, Greib C, Uwamaliya B, Geffard S, Fleury H, Dabis F, Gecsa. Surveillance de la grippe A (H1N1) chez les personnes vivant avec le VIH, Cohorte ANRS CO3 Aquitaine (France), 2009-2010. *BEH* 2011(42):441-444

Bruyand M, Dabis F, Vanhenhede MA, Lazaro E, Neau D, Leleux O, Geffard S, Morlat P, Chêne G, bonnet F, Gecsa. HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008. *J Hepatol* 2011;55:1058-1062

Cascade Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. *Arch Intern Med* 2011;171(17):1560-1569

Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warszawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chêne G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. *Lancet* 2011;377(9777):1580-1587

Cozzi-Lepri A, Prosperi MC, Kjaer J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D. Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. *PLoS One* 2011;6(11):e25665

D. A. D. Study Group, Kamara DA, Worm SW, Reiss P, Rickenbach M, Phillips A, Kirk O, D'Arminio Monforte A, Bruyand M, Law M, De Wit S, Smith CJ, Pradier C, Lundgren J, Sabin C. The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study. *J Infect Dis* 2011;204(4):521-525

de Pommerol M, Hessamfar M, Lawson-Ayayi S, Neau D, Geffard S, Farbos S, Uwamaliya B, Vandenhende MA, Pellegrin JL, Blancpain S, Dabis F, Morlat P. Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort. *Int J STD AIDS* 2011;22(2):67-72

Franrenet S, Moutel G, Raffi F, Dabis F, Bruyand M, Herve C, Leport C, Duchange N. Information that should be given to HIV cohort participants during ongoing research: the viewpoints of patient representatives and research professionals. *J Empir Res Hum Res Ethics* 2011;6(4):76-83

Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR, Cascade Collaboration. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. *AIDS* 2011;25(11):1395-1403

Judd A, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. *AIDS* 2011;25(18):2279-87

Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD, EuroSIDA Study G, and the DADSG. The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology. *Epidemiology* 2011;22(4):516-523

Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. *AIDS* 2011;25(12):1505-1513

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K, on behalf of the Cascade Collaboration in EuroCoord. Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm³: Assessment of Need Following Changes in Treatment Guidelines. *Clin Infect Dis* 2011;53(8):817-825

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Gunthard HF, Chene G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study. *J Acquir Immune Defic Syndr* 2011;58(3):253-260

Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucchi M, Collaboration C. Decline of CD4 T-cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. *AIDS* 2011;25(8):1041-1049

Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Banhegyi D, Clotet B, Lundgren J, Menendez-Arias L, Martinez-Picado J. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. *J Infect Dis* 2011;204(5):741-752

Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Moller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). *HIV Med* 2011;12(7):412-421

Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. *AIDS* 2011;25(18):2259-2268

Richert L, Dehail P, Mercie P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G. High frequency of poor locomotor performance in HIV-infected patients, ANRS CO3 aquitaine Cohort. *AIDS* 2011;25:797-805

Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Hepatitis delta in HIV-infected individuals in Europe. *AIDS* 2011;25(16):1987-1992

van der Helm JJ, Prins M, Del Amo J, Bucher HC, Chêne G, Dorrucchi M, Gill MJ, Hamouda O, Sannes M, Porter K, Geskus RB. The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. *AIDS* 2011;25(8):1083-1091

Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. *AIDS* 2011;25(10):1305-1315

Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Møller N, Mercie P, Lundgren JD, Sabin C. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. *AIDS* 2011;25(12):1497-1504

Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kucherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, Garcia F, Judd A, Porter K, Thiebaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. *Lancet Infect Dis* 2011 11(5):363-671

2012

Alam N, Cortina-Borja M, Goetghebuer T, Marczyńska M, Vigano A, Thorne C. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. *J Acquir Immune Defic Syndr* 2012;59(3):314-324

COHERE, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe, EuroCoord, Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro J, Furrer H, Castagna A, Wit Sd, Munoz J, Kjaer J, Colin C, Grarup J, Chêne G, Bucher H. CD4 Cell Count and the Risk of AIDS or Death in HIVInfected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. *PLoS Med* 2012;9(3):e1001194

COHERE in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G. All-cause mortality in treated HIV-infected adults with CD4 $\geq$ 500/mm³ compared with the general population: evidence from a large European observational cohort collaboration{dagger}. *Int J Epidemiol* 2012;41(2):433-445

Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. *HIV Med* 2012;13(1):62-72

De Wolf F, Sabin C, Kirk O, Thorne C, Chêne G, Porter K. Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. *Clin Invest* 2012;2(3):255-264

HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Effect of hepatitis C treatment on CD4 cell counts and the risk of death in HIV-hepatitis C co-infected patients. *Antivir Ther* 2012 Epub

Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, de Olalla PG, Porter K, del Amo J, Cascade Collaboration in EuroCoord. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. *Clin Infect Dis* 2012;54(1):111-118

Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. *AIDS* 2012;26(3):315-323

Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. *Antivir Ther* 2012 Epub

Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. *HIV Med* 2012;13(2):89-97

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G, CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. *PLoS One* 2012;7(3):e32369

Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. *AIDS* 2012;26(15):1917-1926

Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O. Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. *BMC Infect Dis* 2012;12(1):229

Pursuing Later Treatment Option II (PLATO II) project team, Observational HIV Epidemiological Research Europe (COHERE) Group, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczar D, Mocroft A, Dorrucchi M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheue rG, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. *Lancet Infect Dis* 2012;12(2):119-127

Pursuing Later Treatment Options II (PLATO II) project team, Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Nakagawa F, Lodwick R, Costagliola D, Sighem Av, Torti C, Podzamczar D, Mocroft A, Ledergerber B, Dorrucchi M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, Wit SD, Stephan C, Obel N, Fätkenheuer G, Castagna A, Touloumi G, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. *J Acquir Immune Defic Syndr* 2012;59(3):294-299

Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. *PLoS One* 2012;7(7):e41673

Thorne C, Semenenko I, Malyuta R, Ukraine European Collaborative Study Group in EuroCoord. Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000-10. *Addiction* 2012;107(1):118-28

Worm S, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, Montforte, AD, Law M, Philipps A, Ryom L, Dabis F, Weber R, Sabin C, D:A:D Study Group. Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke. *J Infect Dis* 2012;205(4):535-539

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K, CASCADE Collaboration in EuroCoord. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. *Antivir Ther* 2012;17(6):1039-1048

2013

Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy FA, Mercie P, Greib C, Richert L, Neau D, Catheline G, Dehail P, Dabis F, Morlat P, Dartigues JF, Chêne G, for the Aquitaine Cohort. Cognitive disorders in HIV-infected patients: are they HIV-related? *AIDS* 2013;27(3):391-400

Cazanave C, Lawson-Ayayi S, Hessamfar M, Neau D, Dupon M, Morlat P, Dabis F, de Barbeyrac B, Bebear C, Pereyre S. Prevalence of *Mycoplasma genitalium* Among HIV-Infected Women, Agence Nationale de Recherches sur le SIDA et les hepatites virales CO3 Aquitaine Cohort, France. *Sex Transm Dis* 2013;40(8):653-654

Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. *HIV Med.* 2013 Nov;14(10):614-23.

Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R, DAD Study Group. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *Clin Infect Dis.* 2013 Oct 22;56(6):870-9

Lawson-Ayayi S, Cazanave C, Kpozehouen A, Barthe N, Mehse N, Hessamfar M, Dupon M, Dabis F, Neau D, for the Groupe d'Epidemiologie Clinique du Sida en Aquitaine. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort. *J Acquir Immune Defic Syndr* 2013 62(4):430-435

Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD, EuroSIDA study in EuroCOORD. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. *AIDS.* 2013 Mar 27;27(6):907-18

Monforte AD, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. *AIDS.* 2013 Jan 28;27(3):407-15.

Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Deti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chêne G, Groupe d'Epidemiologie Clinique du Sida en Aquitaine. Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004-2012. *PLoS One* 2013;8(6):e66223

Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD, for EuroSida in EuroCoord. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfecting patients. *PLoS One.* 2013 8(5):e64283.

Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte A, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? *J Hepatol.* 2013 Aug;59(2):213-20.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD, DAD Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. *J Infect Dis.* 2013 May 1;207(9):1359-69.

Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM, Mocroft A, EuroSIDA in EuroCoord. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. *HIV Med.* 2013 Sep;14(8):503-8.

Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J, D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. *AIDS.*

2013 Nov 13;27(17):2735-48.

Sogaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, Servitskiy S, Domingo P, Reiss P, Mocroft A, Kirk O. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. *J Infect.* 2013 May;66(5):439-46.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fatkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. *BMC Infect Dis.* 2013 Oct 09;13:471.

2014

Antiretroviral Therapy Cohort Collaboration (ART-CC). Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US. *Antivir Ther.* 2015;20(1):21-8.

Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczek D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. *Neurology.* 2014 Jul 8;83(2):134-41.

Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N;

Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. *Clin Infect Dis.* 2014 May;58(9):1312-21.

Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, Neau D, Cazanave C, Pellegrin JL, Dabis F, Morlat P, Chêne G; GECSA study group. Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort. *PLoS One.* 2014 Jul 30;9(7):e102671.

IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PC, Fox MP, Gandhi NR, González E, Lee CK, Hoffmann CJ, Kambugu A, Keiser O, Ditangco R, Prozesky H,

Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YM, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. *J Acquir Immune Defic Syndr.* 2014 Jan 1;65(1):e8-16.

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. *BMC Nephrol.* 2014 Mar 25;15:51.

Luz PM, Bruyand M, Ribeiro S, Bonnet F, Moreira RI, Hessamfar M, Campos DP, Greib C, Cazanave C, Veloso VG, Dabis F, Grinsztejn B, Chêne G; IPEC/FIOCRUZ Cohort and the Aquitaine ANRS C03 Study Group. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies. *BMC Infect Dis.* 2014 May 21;14:278.

Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. *Infection.* 2014 Aug;42(4):757-62.

Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD. Deteriorating renal function and clinical outcomes in HIV-positive persons. *AIDS.* 2014 Mar 13;28(5):727-37.

Mocroft A, Ryom L, Reiss P, Furrer H, D'Arminio Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren JD, Kirk O; EuroSIDA in EuroCOORD. A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. *HIV Med.* 2014 Mar;15(3):144-52.

Mocroft A, Lundgren J, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Heuhaus J, Fux C, Moranne O, Morlat P, Johnson M, Ryom L; Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study group. A clinically useful risk-score for chronic kidney disease in HIV infection. *J Int AIDS Soc.* 2014 Nov 2;17(4 Suppl 3):19514.

Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. *PLoS One.* 2014 Jan 28;9(1):e86719.

Peters L, Mocroft A, Soriano V, Rockstroh JK, Kirkby N, Reiss P, Katlama C, Zakharova N, Flisiak R, Lundgren JD; EuroSIDA in EuroCoord. High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. *HIV Med.* 2014 Nov;15(10):615-20.

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. *HIV Med.* 2014 Nov;15(10):595-603.

Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; HIV/TB study group. Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. *Eur Respir J.* 2014 Jan;43(1):166-77.

Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G,

Dehail P; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Decline in locomotor functions over time in HIV-infected patients. *AIDS*. 2014 Jun 19;28(10):1441-9.

Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G, Dehail P; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Handgrip strength is only weakly correlated with physical function in well-controlled HIV infection: ANRS CO3 Aquitaine Cohort. *J Acquir Immune Defic Syndr*. 2014 Jan 1;65(1):e25-7.

Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, Morlat P, Moranne O, Smith C, El-Sadr W, Law M, Lundgren JD. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. *AIDS*. 2014 Jan 14;28(2):187-99.

Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP; EuroSIDA in EuroCOORD. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. *J Infect Dis*. 2014 Jul 15;210(2):234-43.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet*. 2014 Jul 19;384(9939):241-8.

Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. *AIDS*. 2014 Sep 24;28(15):2297-306.

Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, Bonnet F, Lazaro E, Neau D, Fleury H, Dabis F, Morlat P, Masquelier B. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. *PLoS One*. 2014 Jan 27;9(1):e86771.

Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J; EuroSIDA in EuroCoord. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. *PLoS One*. 2014 Jan 31;9(1):e87160.

2015

Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O4, Mocroft A, Peters L, Rockstroh JK; EuroSIDA in EuroCoord. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? *Liver Int* 2015;35(11):2384-91.

Bruyand M, Le Marec F, Lavole A, Leffondre K, Spano JP, Le Moing V, Tattevin P, March L, Cadranel J, Bonnet F, Guiguet M. Protease Inhibitors exposure is not related to lung cancer risk in HIV smoker patients: A nested Case-control Study. *AIDS* 2015;29(9):1105-9.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination

antiretroviral therapy: the D: A: D study. *J Acquir Immune Defic Syndr*. 2015 Apr 15;68(5):568-77.

Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA ; HIV-CAUSAL Collaboration. Boosted Lopinavir-versus boosted Atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis*. 2015;60(8):1262-8.

Cazanave C, Reigadas S, Mazubert C, Bellecave P, Hessamfar M, Le Marec F, Lazaro E, Peytavin G, Bruyand M, Fleury H, Dabis F, Neau D. Switch to Rilpivirine/Emtricitabine/Tenofovir single-tablet regimen of Human Immunodeficiency Virus-1 RNA-suppressed patients, ANRS CO3 Aquitaine Cohort, 2012–2014. *Open Forum Infect Dis* 2015; 2(1):ofv041.

Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based antiretroviral therapy: A multi-cohort European case-control study using centralized ultrasensitive 454 pyrosequencing. *J Antimicrob Chemother* 2015;70(3):930-40.

Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, Moreau JF, Dauchy FA, Cazanave C, Vandenhende MA, Bonnet F, Thiebaut R, Pellegrin I; ANRS CO3 Aquitaine Cohort Study Group. Association of immune-activation and -senescence markers with non AIDS defining comorbidities in HIV suppressed patients. *AIDS* 2015;29(16):2099-108.

Dufouil C, Richert L, Thiébaut R, Bruyand M, Amieva H, Dauchy FA, Dartigues JF, Neau D, Morlat P, Dehail P, Dabis F, Bonnet F, Chêne G; ANRS CO3 Aquitaine Study Group. Diabetes and cognitive decline in a French cohort of patients infected with HIV-1. *Neurology* 2015;85(12):1065-73.

Vandenhende MA, Perrier A, Bonnet F, Lazaro E, Cazanave C, Reigadas S, Chêne G, Morlat P; AIDS Clinical Epidemiology Group of Aquitaine. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study). *Antivir Ther*. 2015;20(6):655-60.

Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Skrahin A, Miro JM, Caylà JA, Girardi E, Bruyand M, Obel N, Podlekareva DN, Lundgren JD, Mocroft A, Kirk O; TB:HIV study group in EuroCoord. Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. *PLoS One*. 2015 Dec 30;10(12):e0145380.

Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Liver-related death among HIV/HCV coinfecting individuals, implications for the era of directly acting antivirals. *AIDS* 2015;29(10):1205-15.

Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d'Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy

among HIV-infected individuals on antiretroviral therapy in Europe and North America. *AIDS* 2015;29(2):221-9.

Late presenters working group in COHERE in EuroCoord: Mocroft A, Lundgren J, Antinori A, Monforte A d'Arminio, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. *Euro Surveill* 2015;20(47).

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV*. 2015;2(8):e335-43.

Mansfeld M, Skrahina A, Shepherd L, Schultze A, Panteleev AM, Miller RF, Miro JM, Zeltina I, Tetrarov S, Furrer H, Kirk O, Grzeszczuk A, Bolokadze N, Matteelli A, Post FA, Lundgren JD, Mocroft A, Efsen A, Podlekareva DN; TB:HIV study group in EuroCoord. Major differences in organisation and availability of health care and medicines for HIV/TB coinfecting patients across Europe. *HIV Med*. 2015 Oct;16(9):544-52.

Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. *AIDS* 2015;29(2):193-200.

Migrants Working Group on behalf of COHERE in EuroCoord. Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. *Lancet HIV*. 2015 Dec;2(12):e540-9.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. *PLoS Med*. 2015 Mar 31;12(3):e1001809.

Mocroft A, Lundgren J, Antinori A, Monforte Ad, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. *Euro Surveill*. 2015;20(47).

Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M, Parczewski M, Lundgren JD, Mocroft A, Kirk O; EuroSIDA in EuroCoord. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. *HIV Med*. 2015 Oct;16(9):533-43.

Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A; EuroSIDA in EuroCOORD. HIV resistance testing and detected drug resistance in Europe. *AIDS* 2015;29(11):1379-89.

Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, Gill MJ, Schwarze-Zander C, Hernandez-Novoa B, Obel N, Kirk O, Abgrall S, Guest J, Samji H, D'Arminio Monforte A, Llibre JM, Smith C, Cavassini M, Burkholder GA, Shepherd B, Crane HM, Sterne J, Morlat P. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. *Antiretroviral Therapy Cohort Collaboration (ART-CC)*. *AIDS* 2015;29(3):373-83.

2016

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. *HIV Med.* 2016 Apr;17(4):255-68.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Canadian Observational Cohort Collaboration (CANOC), UK Collaborative HIV Cohort Study (UKCHIC), Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), May MT, Gill MJ, Wittkop L, Klein M, Sabin C, Harrigan PR, Dunn D, Vehreschild JJ, Rubio R, Mocroft A, Cavassini M, Reiss P, Monforte AD, Zangerle R, Ingle SM, Hill T, Jose S, Sterne JA. Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. *AIDS*. 2016 Jan 28;30(3):503-13.

Boettiger DC, Sabin CA, Grulich A, Ryom L, Bonnet F, Reiss P, Monforte A, Kirk O, Phillips A, Bower M, Fatkenheuer G, Lundgren JD, Law M, Data collection on Adverse events of Anti HIVDsg. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? *AIDS*. 2016 Jun 19;30(10):1629-37.

Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernan MA, Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. *J Acquir Immune Defic Syndr.* 2016 Jun 1;72(2):214-21.

Collin A, Le Marec F, Vandenhende MA, Lazaro E, Duffau P, Cazanave C, Gerard Y, Dabis F, Bruyand M, Bonnet F, ANRS CO3 Aquitaine Cohort Study Group. Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. *ANRS CO3 Aquitaine Cohort, 2000-2012*. *PLoS One*. 2016 Apr 6;11(4):e0152970.

De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Gunthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schuster E, Torti C, van Sighem A, Zangerle R, Descamps D, Chain and COHERE in EuroCoord. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. *J Antimicrob Chemother.* 2016 May;71(5):1352-60.

Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M; D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. *Eur J Prev Cardiol*. 2016 Jan;23(2):214-23.

Hatleberg CI, Ryom L, El-Sadr W, Smith C, Weber R, Reiss P, Fontas E, Dabis F, Law M, Monforte A, De Wit S, Mocroft A, Phillips A, Lundgren JD, Sabin C, Group DADS. Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. *AIDS*. 2016 Mar 4;30(10):1583-96.

Kamara DA, Smith C, Ryom L, Reiss P, Rickenbach M, Phillips A, Mocroft A, De Wit S, Law M, Monforte AD, Dabis F, Pradier C, Lundgren JD, Sabin C. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. *Antivir Ther (Lond)*. 2016;21(6):495-506.

Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F, d'Arminio Monforte A, Smith C, de Wit S, Kirk O, Lundgren JD, Weber R. Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study (D:A:D). *Open Forum Infect Dis*. 2016 Jan;3(1):ofw009.

May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, d'Arminio Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miro JM, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC). Mortality according to CD4 count at start of combination antiretroviral therapy among HIV positive patients followed for up to 15 years after start of treatment: collaborative cohort study. *Clin Infect Dis*. 2016 Jun 15;62(12):1571-7.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. *Lancet HIV*. 2016 Jan;3(1):e23-32.

Ngo Giang Huong N*, Wittkop L* (*co-first author), Judd A, Reiss P, Goetghebuer T, Duiculescu D, Noguera-Julian A, Marczyńska M, Giacchino C, Ene L, Ramos JT, Cellerai C, Klimkait T, Brichard B, Valerius N, Sabin C, Teira T, Obel N, Stephan C, de Wit S, Thorne C, Gibb D, Schwimmer C, Athena Campbell M, Pillay D, Lallemand M. Prevalence and effect of pre-existing drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project. *BMC Infect Dis*. 2016 Nov 8;16(1):654.

Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E, Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O, Tb:HIV Study Group in EuroCoord. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. *Lancet HIV*. 2016 Mar;3(3):e120-31.

Prague M, Commenges D, Gran JM, Ledergerber B, Young J, Furrer H, Thiebaut R. Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. *Biometrics*. 2016 Jul 26;

Ryom L, Lundgren JD, Ross M, Kirk O, Law M, Morlat P, Fontas E, Smit C, Fux CA, Hatleberg CI, de Wit S, Sabin CA, Mocroft A, Group DADS. Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. *J Infect Dis*. 2016 Oct 15;214(8):1212-20.

Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, El-Sadr W, Monforte AD, Mocroft A, Smith C, Fontas E, Dabis F, Phillips A, Sabin C, Group DADS. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. *AIDS*. 2016 Jan 8;30(11):1731-43.

Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren JD. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. *BMC Med*. 2016 14(1):61.

Wyss N, Zwahlen M, Clifford G, Campbell M, Chakraborty R, Bonnet F, Chene G, Bani-Sadr F, Verbon A, Zangerle R, Paparizos V, Prins M, Dronda F, Le Moing V, Antinori A, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Vehreschild JJ, Obel N, Mocroft A, Brockmeyer N, Boue F, Sabin C, Spagnuolo V, Hasse B, De Wit S, Roca B, Egger M, Bohlius J, Cancer Project Working Group for the Collaboration of Observational H. I. V. Epidemiological Research Europe study in EuroCoord. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. *Clin Infect Dis*. 2016 Nov 15;63(10):1373-9.

Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, Smit C, Schommers P, Thornton A, Berenguer J, Peters L, Spagnuolo V, Ammassari A, Antinori A, Roldan EQ, Mussini C, Miro JM, Konopnicki D, Fehr J, Campbell MA, Termote M, Bucher HC, Hepatitis Coinfection, Non Hodgkin Lymphoma project team for the Collaboration of Observational H. I. V. Epidemiological Research Europe in EuroCoord. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. *Ann Intern Med*. 2017 3;166(1):9-17.

2017

Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. *Lancet HIV*. 2017 Aug;4(8):e349-e356.

Bouquemont J, Lawson-Ayayi S, Rigotherier C, Bonnet F, Proust-Lima C, Neau D, Greib C, Miremont-Salamé G, Dabis F, Dupon M, Dauchy FA; for ANRS CO3 Aquitaine Cohort Study Group. Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management. *Nephron*. 2017 Apr 26;136(3).

Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d'Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, Battegay M, Brockmeyer N, Berenguer J, Morlat P, Obel N, De Wit S, Fätkenheuer G, Zangerle R, Ghosn J, Pérez-Hoyos S, Campbell M, Prins M, Chêne G, Meyer L, Dorrucci M, Torti C, Thiébaud R ; Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. *HIV Med*. 2017 Jan;18(1):33-44.

Boyd MA, Mocroft A, Ryom L, Monforte AD, Sabin C, El-Sadr WM, Hatleberg CI, De Wit S, Weber R, Fontas E, Phillips A, Bonnet F, Reiss P, Lundgren J, Law M. Cardiovascular disease

(CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. *PLoS Med.* 2017 Nov 7;14(11):e1002424.

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. *J Acquir Immune Defic Syndr.* 2017 Oct 4.

Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RD, Reiss P; HIV-CAUSAL Collaboration; Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. *Lancet HIV.* 2017 Apr 11.

Chene G, Phillips A, Costagliola D, Sterne JA, Furrer H, Del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbol Brandt R, Friis-Moller N, Raben D, Haerry D, Egger M, Weller I, De Wit S. Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. *Int J Epidemiol.* 2017 Jun 1;46(3):797-797n.

Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, Hamouda O, Estrada Perez V, Leal M, Mocroft A, Garcia De Olalla P, Ammassari A, D'Arminio Monforte A, Mussini C, Segura F, Castagna A, Cavassini M, Grabar S, Morlat P, De Wit S, Lambotte O, Meyer L; HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. *PLoS ONE.* 2017;12(4):e0173893.

Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA.. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. *J Acquir Immune Defic Syndr.* 2017 Nov 1;76(3):311-8.

Ozanne A, Duffau P, Dauchy FA, Rigotherier C, Terrien C, Lazaro E, Cazanave C, Lawson-ayayi S, Bonnet F, Blanco P, Wittkop L#, Pellegrin I for then CIADIS sub-study in the ANRS CO3 Aquitaine cohort study group. #These authors contributed equally Activation, Senescence and Inflammation Markers in HIV Patients: Association with renal function. *AIDS.* 2017 May 15;31(8):1119-1128.

Picat M-Q, Pellegrin I, Bitard J, Wittkop L, Proust-Lima C, Liqueur B, Moreau JF, Bonnet F, Blanco P, Thiebaut R, ANRS CO3 Aquitaine Cohort. Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients. *PLoS ONE.* 2017;12(1):e0169164

Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. *Aids.* 2017 Jun 01;31(9):1261-70.

Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.D:A:D study group.AIDS. 2017 Mar 28. doi: 10.1097 1.

Shepherd L, Ryom L, Law M, Hatleberg CI, de Wit S, Monforte AD, Battegay M, Phillips A, Bonnet F, Reiss P, Pradier C, Grulich A, Sabin C, Lundgren J, Mocroft A. Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. J Natl Cancer Inst. 2017 Dec 18.

Thiébaud R, Hue S, Le Marec F, Lelièvre JD, Dupon M, Foucat E, Lazaro E, Dabis F, Duffau P, Wittkop L, Surenaud M, Pellegrin I, Lacabaratz C, Bonnet F, Lévy Y, for the ANRS CO3 Aquitaine Cohort. Serum ST2 level is an independent predictor of all-cause mortality in HIV infected patients. Aquitaine Cohort, France. AIDS 2017 Aug 28. [Epub ahead of print]

Valdes A, Cazanave C, Dabis F, Neau D, Lacoste D, Gaborieau V, Farbos S, Dworkin MS, ANRS CO3 Aquitaine Cohort. Knowledge, behaviors, and attitudes of HIV-infected men about syphilis. Med Mal Infect. 2017 Sep 21.

Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIEV2e Study Group. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. J Antimicrob Chemother. 2017 Oct 1;72(10):2869–78.

2018

Achhra AC, Sabin C, Ryom L, Hatleberg C, d'Aminio Monforte A, Wit S, Phillips A, Pradier C, Weber R, Reiss P, El-Sadr W, Bonnet F, Mocroft A, Lundgren J, Law MG; D:A:D study group. Body Mass Index and The Risk of Serious Non-Aids Events and All Cause Mortality in Treated Hiv-Positive Individuals: D: A: D Cohort Analysis. J Acquir Immune Defic Syndr. 2018 May 3.

AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS. 2018 Nov 28;32(18):2777-2786.

Barger D, Leleux O, Conte V, Sapparrart V, Gapillout M, Crespel I, Erramouspe M, Delveaux S, Dabis F, Bonnet F. Integrating Electronic Patient-Reported Outcome Measures into Routine HIV Care and the ANRS CO3 Aquitaine Cohort's Data Capture and Visualization System (QuAliV): Protocol for a Formative Research Study. JMIR Res Protoc. 2018 Jun 7;7(6):e147.

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):102-109.

Duffau P, Ozanne A, Bonnet F, Lazaro E, Cazanave C, Blanco P, Rivière E, Desclaux A, Hyernard C, Gensous N, Pellegrin I, Wittkop L. Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults. *AIDS*. 2018 May 11.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. *J Int AIDS Soc*. 2018 Mar;21(3).

Hatleberg CI, Ryom L, d'Arminio Monforte A, Fontas E, Reiss P, Kirk O, El-Sadr W, Phillips A, de Wit S, Dabis F, Weber R, Law M, Lundgren JD, Sabin C; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *HIV Med*. 2018 Oct;19(9):605-618.

IeDEA and COHERE Cohort Collaborations. Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. *Clin Infect Dis*. 2018 Mar 5;66(6):893-903.

Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. *J Int AIDS Soc*. 2018 Jan;21(1).

Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, Phillips A, Weber R, Fontas E, d'Arminio Monforte A, De Wit S, Dabis F, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. *Lancet HIV*. 2018 Jun;5(6):e291-e300.

Rohner E; AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. Non-Hodgkin lymphoma risk in adults living with HIV across five continents: a multicohort study. *AIDS*. 2018 Sep 17.

Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, Weber R, Pradier C, De Wit S, Law M, Monforte AD, Lundgren J, Mocroft A, Phillips AN, Sabin CA; D:A:D Study group. Associations between serum albumin and serious non-AIDS events among people living with HIV. *AIDS*. 2018 May 28.

Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group. Abacavir use and risk of recurrent myocardial infarction. *AIDS*. 2018 Jan 2;32(1):79-88.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; D:A:D Study group. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in HIV-positive Persons: The D:A:D Study. *Clin Infect Dis*. 2018 Jun 14.

2019

Barger D, Leleux O, Conte V, Sapparrart V, Gapillout M, Crespel I, Erramouspe M, Delveaux S, Wittkop L, Dabis F, Bonnet F. Usability testing of a Web-based solution for the collection of electronic patient-reported outcomes in people living with HIV in Nouvelle-Aquitaine, France. *JMIR* 2/06/2019:15013

Besson C, Noel N, Lancar R, Prevot S, Algarte-Genin M, Rosenthal E, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Cheret A, Arvieux C, Katlama C, Salmon D, Boué F, Costello R, Hendel-Chavez H, Taoufik Y, Fontaine H, Coppo P, Mounier N, Delobel P, Costagliola D; Lymphovir and FHDH study groups. HCV or HBV coinfection and lymphoma risk in people living with HIV. *AIDS*. 2019 Dec 10.

Deborde M, Pereyre S, Puges M, Bebear C, Desclaux A, Hessamfar M, Le Roy C, Le Marec F, Dabis F, Cazanave C. High prevalence of *Mycoplasma genitalium* infection and macrolide resistance in patients enrolled in HIV pre-exposure prophylaxis program. *Med Mal Infect*. 2019 Mar 23.

Ducours M, Alleman L, Puges M, Deborde M, Hessamfar M, Le Marec F, Dabis F, Pereyre S, Bebear C, Desclaux A, Cazanave C. Incidence of sexually transmitted infections during Pre-Exposure Prophylaxis for HIV: a worrying outcome at two years! Soumis dans *Sexually Transmitted Infections*

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. *Stat Med*. 2019 Jun 15;38(13):2428-2446.

Hatleberg CI, Ryom L, Kamara D, De Wit S, Law M, Phillips A, Reiss P, D'Arminio Monforte A, Mocroft A, Pradier C, Kirk O, Kovari H, Bonnet F, El-Sadr W, Lundgren JD, Sabin C; D:A:D Study Group. Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. *E Clinical Medicine*. 2019 Aug 11;13:91-100.

Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term virological suppression on first-line efavirenz+tenofovir+emtricitabine/lamivudine for HIV-1. *AIDS*. 2019 Mar 15;33(4):745-751.

Oleary F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Günthard HF, Bernasconi E, Boeni J, D'Arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A. Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. *Open Forum Infect Dis*. 2019 Dec 8;6(12):ofz500

Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, Ross M, **Morlat P**, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With

Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *J Infect Dis.* 2019 Oct 8;220(10):1629-1634.

Ryom L, Lundgren JD, Law M, Kirk O, El-Sadr W, Bonnet F, Weber R, Fontas E, Monforte AD, Phillips A, Reiss P, de Wit S, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group. Serious clinical events in HIV-positive persons with chronic kidney disease (CKD). *AIDS.* 2019 Aug 2.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El Sadr W, Lundgren J, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. *Clin Infect Dis.* 2019 Feb 1;68(4):650-657.

Trickey A, van Sighem A, Stover J, Abgrall S, Grabar S, Bonnet F, Berenguer J, Wyen C, Casabona J, d'Arminio Monforte A, Cavassini M, Del Amo J, Zangerle R, Gill MJ, Obel N, Sterne JAC, May MT. Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings. *AIDS.* 2019 Dec 15;33 Suppl 3:S271-S281.

Vourli G, Pharris A, Cazein F, Costagliola D, Dabis F, Del Amo J, Delpech V, Díaz A, Girardi E, Gourlay A, Gunsenheimer-Bartmeyer B, Hernando V, Nikolopoulos G, Porter K, Rosińska M, Sabin C, Suligoi B, Supervie V, Wit F, Touloumi G. Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population? *AIDS.* 2019 Jan 27;33(1):133-143.

Wandeler G, Mauren E, Atkinson A, Dufour JF, Kraus D, Reiss P, Peters L, Dabis F, Fehr J, Bernasconi E, van der Valk M, Smit C, Gærde LK, Rockstroh J, Neau D, Bonnet F, Rauch A; Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. *J Hepatol.* 2019 Apr 6. pii: S01688278(19)30226-0.

Willemse S, Smit C, Sogni P, Sarcletti M, Uberti-Foppa C, Wittkop L, Raben D, d'Arminio Monforte A, Dabis F, Van Der Valk M; Hepatocellular Carcinoma Screening Project Working Group for the Collaboration of Observational HIV on behalf of Epidemiological Research Europe (COHERE) In EuroCoord. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV-patients with cirrhosis. *J Viral Hepat.* 2019 May 28.

2020

Atkinson A, Zwahlen M, Barger D, d'Arminio Monforte A, De Wit S, Ghosn J, Girardi E, Svedhem-Johansson V, **Morlat P**, Mussini C, Noguera-Julian A, Stephan C, Touloumi G, Kirk O, Mocroft A, Reiss P, Miro JM, Carpenter JR, Furrer H; Opportunistic Infections Project Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Withholding primary Pcp prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE. *Clin Infect Dis.* 2020 May 25:ciaa615. doi: 10.1093/cid/ciaa615. Epub ahead of print. PMID: 32448894.

Barger D, Hessamfar M, Neau D, Vareil MO, Lazaro E, Duffau P, Rouanes N, Leleux O, Le Marec F, Erramouspe M, Wittkop L, Dabis F, Bonnet F. Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliv ancillary study. *Health Qual Life Outcomes.* 2020 Jul 10;18(1):220. doi: 10.1186/s12955-020-01451-8. PMID: 32650781; PMCID: PMC7350695.

Bonnet F, Le Marec F, Leleux O, Gerard Y, Neau D, Lazaro E, Duffau P, Caubet O, Vandenhende MA, Mercie P, Cazanave C, Dabis F. Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort. *BMC Infect Dis*. 2020 Nov 16;20(1):850. doi: 10.1186/s12879-020-05593-4. PMID: 33198667; PMCID: PMC7670698.

Chaussade H, Tumiotto C, Le Marec F, Leleux O, Lefèvre L, Lazaro E, Lafon ME, Nyamankolly E, Duffau P, Neau D, Bellecave P, Bonnet F. A Low Level of Darunavir Resistance-Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort. *Open Forum Infect Dis*. 2020 Nov 19;7(12):ofaa567. doi: 10.1093/ofid/ofaa567. PMID: 33409332; PMCID: PMC7772944.

d'Arminio Monforte A, **Bonnet F**, Bucher HC, Pourcher V, Pantazis N, Pelchen-Matthews A, Touloumi G, Wolf E. What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. *HIV Med*. 2020 Sep;21 Suppl 2:3-16. doi: 10.1111/hiv.12935. PMID: 32881311.

Late Presentation Working Groups in EuroSIDA and COHERE. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. *BMC Infect Dis*. 2020 Oct 7;20(1):728. doi: 10.1186/s12879-020-05261-7. PMID: 33028235; PMCID: PMC7541282.

leDEA and COHERE in EuroCoord Cohort Collaboration. All-cause mortality after antiretroviral therapy initiation in HIV-positive women from Europe, Sub-Saharan Africa and the Americas. *AIDS*. 2020 Feb 1;34(2):277-289. doi: 10.1097/QAD.0000000000002399. PMID: 31876592; PMCID: PMC6948801.

Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Papanizos V, **Bonnet F**, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J. Cervical cancer risk in women living with HIV across four continents: A multicohort study. *Int J Cancer*. 2020 Feb 1;146(3):601-609.

Ryom L, Lundgren JD, Reiss P, Ross M, Kirk O, Fux CA, **Morlat P**, Fontas E, Smith C, De Wit S, d'Arminio Monforte A, El Sadr W, Hatleberg C, Phillips A, Sabin C, Law M, Mocroft A; D:A:D Study Group. The impact of immunosuppression on chronic kidney disease in people living with HIV; the D:A:D study. *J Infect Dis*. 2020 Jul 8:jiaa396. doi: 10.1093/infdis/jiaa396. Epub ahead of print. PMID: 32640015.

Teruel E, Vandenhende MA, Neau D, Lazaro E, Duffau P, Vareil MO, Cazanave C, Perrier A, le Marec F, Leleux O, Bonnet F, Wittkop L. Statin use and risk of severe bacterial infection in a population living with HIV: prospective cohort study of the ANRS CO3 Aquitaine Cohort 2000-2018. *Clin Microbiol Infect*. 2020 Dec 1:S1198-743X(20)30715-1. doi: 10.1016/j.cmi.2020.11.019. Epub ahead of print. PMID: 33276140.

Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit FWNM, **Bonnet F**, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier-Pfistershammer K, Guest JL, Shepherd L, Teira R, d'Arminio Monforte A, Del Amo J, Justice A, Costagliola D, Sterne JAC. Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. *Int J Cancer*. 2020 Jun 1;146(11):3134-3146. doi: 10.1002/ijc.32895. Epub 2020 Mar 12. PMID: 32003460; PMCID: PMC7187452.

II.1. ART-CC, Antiretroviral Therapy Cohort Collaboration

N = 33

2002

Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, Collaboration ARTC. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360(9327):119-129

2003

Chêne G, Sterne JAC, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, deWolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME, ART Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. *Lancet* 2003;362(9385):679-686

2005

Antiretroviral Therapy Cohort Collaboration, d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. *Arch Intern Med* 2005;165(4):416-23

Antiretroviral Therapy Cohort Collaboration, Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fatkenheuer G, Sterne JA. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. *Clin Infect Dis* 2005;41(12):1772-1782

May M, Porter K, Sterne JA, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. *J Clin Epidemiol* 2005;58(10):1033-1041

Sabine C, on behalf of the Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? *AIDS* 2005;19(17):1995-2000

2006

Antiretroviral Therapy Cohort Collaboration, Hogg RS, May M, Phillips AN, Costagliola D, Sterne J, Sabin C, de Wolf F, Ledergerber B, D'Arminio Monforte A, Justice AC, Gill J, Fusco G, Staszewski S, Rockstroh J, Chêne G, Egger M. Rates of disease progression according to initial HAART regimen. A collaborative analysis of 12 prospective studies. *J Infect Dis* 2006;194(5):612-622

Antiretroviral Therapy Cohort Collaboration, May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fatkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. *Lancet* 2006;368(9534):451-458

Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M, Antiretroviral Therapy in Lower Income Countries C, groups ARTCC. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 2006;367(9513):817-824

2007

Antiretroviral Therapy Cohort Collaboration, May M, Sterne J, Sabin C, Costagliola D, Justice A, Thiébaud R, Gill J, Phillips AN, Reiss P, Hogg B, Ledergerber B, d'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. *AIDS* 2007;21(9):1185-97

Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Meda JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borgh S, Schechter M, ART-LINC Collaboration. Tuberculosis following initiation of antiretroviral therapy in low-income and high-income countries. *Clin Infect Dis* 2007;45(1):1518-1524

Sterne J, May M, Sabin C, Phillips A, Costagliola D, Chêne G, Justice A, de Wolf F, Hogg B, Battegay M, D'Arminio Monforte A, Fätkenheuer G, Staszewski S, Gill J, Egger M, Antiretroviral Therapy Cohort C. Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy. Collaborative Analysis of Cohorts of HIV-1-Infected Patients. *J Acquir Immune Defic Syndr* 2007;46(5):607-615

2008

Harris RJ, Sterne J, Abgrall S, Dabis F, Reiss P, Saag M, Phillips A, Chêne G, Gill J, Justice A, Rockstroh J, Sabin C, Mocroft A, Bucher HC, Hogg RS, D'Arminio Monforte A, May M, Egger M, Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. *Antivir Ther* 2008;13(8):959-967

Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M, Antiretroviral Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 2008;372(9635):293-299

Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Gunthard HF, Dabis F, Hogg R, de Wolf F, Fätkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miro JM, Staszewski S, Sterne JA, Art CC. Does Short-term Virologic Failure Translate to Clinical Events in ARV-naïve Patients Initiating ART in Clinical Practice? *AIDS* 2008;22(18):2481-2492

2009

Antiretroviral Therapy Cohort Collaboration, Art CC, Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS* 2009;23(16):2199-208

Antiretroviral Therapy Cohort Collaboration, Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. *Clin Infect Dis* 2009;48(8):1138-1151

Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris DR, May M, Hogg B, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, Von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. *Int J Epidemiol* 2009;38(6):1624-1633

Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczek D, Fatkenheuer G, Staszewski S, Gill J, Sterne JA, Art CC. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. *J Acquir Immune Defic Syndr* 2009;52(3):357-363

2010

Antiretroviral Therapy Cohort Collaboration, Gill J, May M, Lewden C, Saag M, Mugavero M, Reiss P, Ledergerber B, Mocroft A, Harris R, Fux CA, Justice A, Costagliola D, Casabona J, Hogg RS, Khaykin P, Lampe F, Vehreschild J, Sterne JA, Egger M, Brodt HR, Chêne G, Dabis F, Monforte AD, de Wolf F, Fatkenheuer G, Guest J, Kirk O, Kitahata M, Sterling T. Causes of Death in HIV1-Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies. *Clin Infect Dis* 2010;50(10):1387-1396

2011

Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Gunthard HF, Chene G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study. *J Acquir Immune Defic Syndr* 2011;58(3):253-260

2012

Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. *HIV Med* 2012;13(2):89-97

2013

/

2014

Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. *Clin Infect Dis*. 2014 May;58(9):1312-21.

IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PC, Fox MP, Gandhi NR, González E, Lee CK, Hoffmann CJ, Kambugu A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YM, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. *J Acquir Immune Defic Syndr*. 2014 Jan 1;65(1):e8-16.

Antiretroviral Therapy Cohort Collaboration (ART-CC). Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US. *Antivir Ther*. 2015;20(1):21-8.

2015

Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, Gill MJ, Schwarze-Zander C, Hernandez-Novoa B, Obel N, Kirk O, Abgrall S, Guest J, Samji H, D'Arminio Monforte A, Llibre JM, Smith C, Cavassini M, Burkholder GA, Shepherd B, Crane HM, Sterne J, Morlat P. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. *Antiretroviral Therapy Cohort Collaboration (ART-CC)*. *AIDS* 2015;29(3):373-83.

2016

May MT, Vehreschild JJ, Trickey A, Obel N, Reiss P, Bonnet F, Mary-Krause M, Samji H, Cavassini M, Gill MJ, Shepherd LC, Crane HM, d'Arminio Monforte A, Burkholder GA, Johnson MM, Sobrino-Vegas P, Domingo P, Zangerle R, Justice AC, Sterling TR, Miro JM, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC). Mortality according to CD4 count at start of combination antiretroviral therapy among HIV positive patients followed for up to 15 years after start of treatment: collaborative cohort study. *Clin Infect Dis*. 2016 Jun 15;62(12):1571-7.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Canadian Observational Cohort Collaboration (CANOC), UK Collaborative HIV Cohort Study (UKCHIC), Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), May MT, Gill MJ, Wittkop L, Klein M, Sabin C, Harrigan PR, Dunn D, Vehreschild JJ, Rubio R, Mocroft A, Cavassini M, Reiss P, Monforte AD, Zangerle R, Ingle SM, Hill T, Jose S, Sterne JA. Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. *AIDS*. 2016 Jan 28;30(3):503-13.

2017

Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. *Lancet HIV*. 2017 Aug;4(8):e349-e356.

2018

Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavassini M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling

TR; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. *J Int AIDS Soc.* 2018 Jan;21(1).

2019

Trickey A, van Sighem A, Stover J, Abgrall S, Grabar S, Bonnet F, Berenguer J, Wyen C, Casabona J, d'Arminio Monforte A, Cavassini M, Del Amo J, Zangerle R, Gill MJ, Obel N, Sterne JAC, May MT. Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings. *AIDS.* 2019 Dec 15;33 Suppl 3:S271-S281.

2020

Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit FWNM, **Bonnet F**, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier-Pfistershammer K, Guest JL, Shepherd L, Teira R, d'Arminio Monforte A, Del Amo J, Justice A, Costagliola D, Sterne JAC. Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. *Int J Cancer.* 2020 Jun 1;146(11):3134-3146. doi: 10.1002/ijc.32895. Epub 2020 Mar 12. PMID: 32003460; PMCID: PMC7187452

II.2. CASCADE, Concerted Action on SeroConversion to AIDS and Death in Europe N = 41

2000

Cascade European Collaborative Project, Babiker A, Darby S, De Angelis D, Ewart D, Porter K. Time from HIV-1 seroconversion to AIDS and death before widespread use of HAART: a collaborative re-analysis. *Lancet* 2000;355(9210):1131-1137

Cascade European Collaborative Project, Porter K. Survival after introduction of HAART in people with known duration of HIV-1 infection. *Lancet* 2000;355(9210):1158-1159

Porter K, Babiker A, Walker AS, Darbyshire J, Gill N, Collaboration C. Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time observational studies; results from CASCADE. *AIDS* 2000;14(13):1899-1906

Porter K, Babiker A, Walker AS, Darbyshire J, Gill N, Collaboration C. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. *HIV Med* 2000;1(4):224-231

2001

Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker AS, Collaboration C. Is the Time From HIV Seroconversion a Determinant of the Risk of AIDS After Adjustment for Updated CD4 Cell Counts? *J Acquir Immune Defic Syndr* 2001;28(2):158-165

Cascade European Collaborative P. The relationships between the HIV test interval, demographic factors and HIV disease progression. *Epidemiol Infect* 2001;127:91-100

2002

Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker AS, Collaboration C. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. *Int J Epidemiol* 2002;31(5):951-958

2003

Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker AS, Collaboration C. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. *Lancet* 2003;362(9392):1267-1274

Babiker A, Darbyshire J, Pezzotti P, Porter K, Prins M, Sabin C, Walker AS, Collaboration C. Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. *J Acquir Immune Defic Syndr* 2003;32(3):303-310

Babiker A, Darbyshire J, Pezzotti P, Porter K, Prins M, Sabin C, Walker AS, Collaboration C. Impact of Tuberculosis on HIV Disease Progression in Persons With Well-Documented Time of HIV Seroconversion. *J Acquir Immune Defic Syndr* 2003;32(2):184-190

Clements M, Law M, Pedersen C, Kaldor J, Collaboration C. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. *HIV Med* 2003;4(4):332-337

Touloumi G, Pantazis N, Babiker A, Walker AS, Katsarou O, Hatzakis A, Karafoulidou A, Porter K, Darbyshire J, Casc ADEC. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. *J Acquir Immune Defic Syndr* 2003;34(1):76-83

2004

Cascade Collaboration, Bhaskaran K, Brettle R, Porter K, Walker AS. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. *AIDS* 2004;18(4):673-681

Cascade Collaboration, Phillips AN, Pezzotti P. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. *AIDS* 2004;18(1):51-58

Collaboration of HIV Cohorts, Phillips AN, Ledergerber B, Lundgren J, Hogg B, d'Arminio Monforte A, Castelli F, Walker AS, Staszewski S, Thiébaut R, Gazzard BG, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D. Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound. *J Infect Dis* 2004;190(4):675-687

2005

Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jorgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kucherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, K P, Collaboration C. Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003. *J Acquir Immune Defic Syndr* 2005;40(5):505-511

Thiébaut R, Jacqmin-Gadda H, Babiker A, Commenges D, Collaboration C. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4⁺ cell count and HIV RNA viral load in response to treatment of HIV infection. *Stat Med* 2005;24(1):65-82

2006

Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, S J, van der Hoek L, Cascade Collaboration. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4⁺ T-cell count and HIV-1 RNA load. *Antivir Ther* 2006;11(2):173-178

Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kucherer C, Poggensee G, Gill J, Porter K, Collaboration C. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. *AIDS* 2006;20(1):21-28

Thiébaut R, Jacqmin-Gadda H, Walker S, Sabin C, Prins M, Del Amo J, Porter K, Dabis F, Chêne G. Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion. *HIV Med* 2006;7(1):1-9

2007

Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber J, Collaboration C. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. *AIDS* 2007;21(10):1283-1291

2008

Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K, Collaboration C. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. *JAMA* 2008;300(1):51-59

Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucchi M, Sabin C, Phillips A, Porter K. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. *Ann Neurol* 2008;63(2):213-221

Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K, Collaboration C. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. *J Infect Dis* 2008;197(3):398-404

Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A. Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). *Open AIDS J* 2008;2:3-9

Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernandez-Aguado I, Meyer L, Porter K, del Amo J, Collaboration C. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. *Am J Epidemiol* 2008;168(5):532-540

Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K, Collaboration C. The effect of antiretroviral treatment of different durations in primary HIV infection. *AIDS* 2008;22(18):2441-2450

Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, Porter K. Rates and Determinants of Virologic and Immunological Response to HAART Resumption After Treatment Interruption in HIV-1 Clinical Practice. *J Acquir Immune Defic Syndr* 2008;49(5):492-498

2009

Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NKT, Bruun Jorgensen L, de Mendoza C, Bhaskaran K, Gill ON, Johnson AL, Pillay D, Collaboration C. Phylogenetic Reconstruction of Transmission Events from Individuals with Acute HIV Infection: Toward More-Rigorous Epidemiological Definitions. *J Infect Dis* 2009;199(3):427-431

Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucchi M, Hamouda O, Prins M, Walker AS, Porter K, Sabin C, Chêne G, Collaboration C. Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. *CASCADE, 1996-2006. AIDS* 2009;23(13):1743-1753

2010

Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K, Collaboration C. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. *AIDS* 2010;24(17):2697-2704

Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chene G, Mussini C, Porter K, Bucher HC. Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy-The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. *PLoS Med* 2010;7(2):e1000239

2011

Cascade Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. *Arch Intern Med* 2011;171(17):1560-1569

Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR, casca DEC. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. *AIDS* 2011;25(11):1395-1403

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K, on behalf of the CCiE. Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm³: Assessment of Need Following Changes in Treatment Guidelines. *Clin Infect Dis* 2011;53(8):817-825

Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucci M, Collaboration C. Decline of CD4 T-cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. *AIDS* 2011;25(8):1041-1049

van der Helm JJ, Prins M, Del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill MJ, Hamouda O, Sannes M, Porter K, Geskus RB. The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. *AIDS* 2011;25(8):1083-1091

2012

Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, de Olalla PG, Porter K, del Amo J, Cascade Collaboration in EuroCoord. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. *Clin Infect Dis* 2012;54(1):111-118

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. *PLoS One* 2012;7(3):e32369

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. *Antivir Ther* 2012;17(6):1039-1048

2013

/

2014

Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. *PLoS One*. 2014 Jan 28;9(1):e86719.

2015

/

2016

/

2017

/

2018

/

2019

/

2020

/

II.3. COHERE / Eurocoord

Collaboration of Observational HIV Epidemiological Research Europe

N = 45

2008

Sabin C, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chêne G, Lundgren J, Cohere. Response to combination antiretroviral therapy: variation by age. *AIDS* 2008;22(12):1463-1472

2009

COHERE, Collaboration of Observational HIV Epidemiological Research Europe study group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro J, Lundgren DJ, Chêne G, Egger M. Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study. *Antivir Ther* 2009;14(8):1065-1074

COHERE, Collaboration of Observational HIV Epidemiological Research Europe study group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chêne G, Lundgren J, Egger M. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. *AIDS* 2009;23(15):2029-2037

2010

COHERE, Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H. Is it safe to discontinue primary *Pneumocystis jirovecii* pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? *Clin Infect Dis* 2010;51(5):611-619

Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucchi M, Ledergerber B, Mocroft A, Podzamczar D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, Garcia F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warszawski J, Thorne C, Masip J, Perez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Gunthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chêne G, Lundgren JD, Phillips AN. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. *Arch Intern Med* 2010;170(5):410-419

2011

Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. *Antivir Ther* 2011;16(6):895-903

Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warszawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chêne G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. *Lancet* 2011;377(9777):1580-1587

Judd A. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. *AIDS* 2011;25(18):2279-2287

Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. *AIDS* 2011;25(18):2259-2268

Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kucherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, Garcia F, Judd A, Porter K, Thiebaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. *Lancet Infect Dis* 2011 11(5):363-671

2012

Alam N, Cortina-Borja M, Goetghebuer T, Marczyńska M, Vigano A, Thorne C. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. *J Acquir Immune Defic Syndr* 2012;59(3):314-324

COHERE, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe, EuroCoord, Young J, Psychogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro J, Furrer H, Castagna A, Wit Sd, Munoz J, Kjaer J, Colin C, Grarup J, Chêne G, Bucher H. CD4 Cell Count and the Risk of AIDS or Death in HIVInfected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. *PLoS Med* 2012;9(3):e1001194

COHERE, The Collaboration of Observational HIV Epidemiological Research Europe, in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G. All-cause mortality in treated HIV-infected adults with CD4 $\geq 500/\text{mm}^3$ compared with the general population: evidence from a large European observational cohort collaboration{dagger}. *Int J Epidemiol* 2012;41(2):433-445

Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. *HIV Med* 2012;13(1):62-72

De Wolf F, Sabin C, Kirk O, Thorne C, chène G, Porter K. Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. *Clin Invest* 2012;2(3):255-264

HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Effect of hepatitis C treatment on CD4 cell counts and the risk of death in HIV-hepatitis C co-infected patients. *Antivir Ther* 2012 Epub

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. *PLoS One* 2012;7(3):e32369

Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. *AIDS* 2012;26(15):1917-1926

Pursuing Later Treatment Option II (PLATO II) project team, Observational HIV Epidemiological Research Europe (COHERE) Group, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczar D, Mocroft A, Dorrucchi M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheue rG, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. *Lancet Infect Dis* 2012;12(2):119-127

Pursuing Later Treatment Options II (PLATO II) project team, Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Nakagawa F, Lodwick R, Costagliola D, Sighem Av, Torti C, Podzamczar D, Mocroft A, Ledergerber B, Dorrucchi M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, Wit SD, Stephan C, Obel N, Fätkenheuer G, Castagna A, Touloumi G, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. *J Acquir Immune Defic Syndr* 2012;59(3):294-299

Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. *PLoS One* 2012;7(7):e41673

Thorne C, Semenenko I, Malyuta R. Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000-10. *Addiction* 2012;107(1):118-128

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. *Antivir Ther* 2012;17(6):1039-1048

2013

/

2014

Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. *AIDS*. 2014 Sep 24;28(15):2297-306.

2015

Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. *AIDS* 2015;29(2):193-200.

Migrants Working Group on behalf of COHERE in EuroCoord. Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. *Lancet HIV*. 2015 Dec;2(12):e540-9.

Mocroft A, Lundgren J, Antinori A, Monforte Ad, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D, De Wit S, Fätkenheuer G, Furrer H, Jadand C, Johnson A, Lazanas M, Leport C, Moreno S, Mussini C, Obel N, Post F, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Loano I, Torti C, Warszawski J, Wittkop L, Zangerle R, Chene G, Raben D, Kirk O. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. *Euro Surveill*. 2015;20(47).

2016

De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Gunthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schuster E, Torti C, van Sighem A, Zangerle R, Descamps D, Chain and COHERE in EuroCoord. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. *J Antimicrob Chemother*. 2016 May;71(5):1352-60.

Wang Q, De Luca A, Smith C, Zangerle R, Sambatakou H, Bonnet F, Smit C, Schommers P, Thornton A, Berenguer J, Peters L, Spagnuolo V, Ammassari A, Antinori A, Roldan EQ, Mussini C, Miro JM, Konopnicki D, Fehr J, Campbell MA, Termote M, Bucher HC, Hepatitis Coinfection, Non Hodgkin Lymphoma project team for the Collaboration of Observational H. I. V. Epidemiological Research Europe in EuroCoord. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. *Ann Intern Med*. 2017 3;166(1):9-17.

Wyss N, Zwahlen M, Clifford G, Campbell M, Chakraborty R, Bonnet F, Chene G, Bani-Sadr F, Verbon A, Zangerle R, Paparizos V, Prins M, Dronda F, Le Moing V, Antinori A, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Vehreschild JJ, Obel N, Mocroft A, Brockmeyer N, Boue F, Sabin C, Spagnuolo V, Hasse B, De Wit S, Roca B, Egger M, Bohlius J, Cancer Project Working Group for the Collaboration of Observational H. I. V. Epidemiological Research Europe study in EuroCoord. Changing Incidence and Risk Factors for Kaposi Sarcoma by

Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. *Clin Infect Dis*. 2016 Nov 15;63(10):1373-9.

2017

Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d'Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, Battegay M, Brockmeyer N, Berenguer J, Morlat P, Obel N, De Wit S, Fätkenheuer G, Zangerle R, Ghosn J, Pérez-Hoyos S, Campbell M, Prins M, Chêne G, Meyer L, Dorrucchi M, Torti C, Thiébaut R ; Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. *HIV Med*. 2017 Jan;18(1):33-44.

Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, Hamouda O, Estrada Perez V, Leal M, Mocroft A, Garcia De Olalla P, Ammassari A, D'Arminio Monforte A, Mussini C, Segura F, Castagna A, Cavassini M, Grabar S, Morlat P, De Wit S, Lambotte O, Meyer L; HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. *PLoS ONE*. 2017;12(4):e0173893.

Chene G, Phillips A, Costagliola D, Sterne JA, Furrer H, Del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbol Brandt R, Friis-Møller N, Raben D, Haerry D, Egger M, Weller I, De Wit S. Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. *Int J Epidemiol*. 2017 Jun 1;46(3):797-797n.

Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucchi M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIEV2e Study Group. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. *J Antimicrob Chemother*. 2017 Oct 1;72(10):2869-78.

2018

AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. Non-Hodgkin lymphoma risk in adults living with HIV across five continents. *AIDS*. 2018 Nov 28;32(18):2777-2786.

IeDEA and COHERE Cohort Collaborations . Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs.*ClinInfect Dis*.2018Mar 5;66(6):893-903.

Caniglia EC,Phillips A,Porter K,Sabin CA,Winston A,Logan R,Gill J, Vandenhende MA,Barger D, Lodi S,Moreno S,Arribas JR,Pacheco A,Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R,van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. *J Acquir Immune Defic*

Syndr.2018Jan 1;77(1):102-109.

Rohner E; AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord. Non-Hodgkin lymphoma risk in adults living with HIV across five continents: a multicohort study. *AIDS*.2018Sep17.

2019

Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term virological suppression on first-line efavirenz+tenofovir+emtricitabine/lamivudine for HIV-1. *AIDS*.2019Mar 15;33(4):745-751.

Vourli G, Pharris A, Cazein F, Costagliola D, Dabis F, Del Amo J, Delpech V, Díaz A, Girardi E, Gourlay A, Gunsenheimer-Bartmeyer B, Hernando V, Nikolopoulos G, Porter K, Rosińska M, Sabin C, Suligoi B, Supervie V, Wit F, Touloumi G. Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population? *AIDS*.2019Jan27;33(1):133-143.

Willemse S, Smit C, Sogni P, Sarcletti M, Uberti-Foppa C, Wittkop L, Raben D, D'Arminio Monforte A, Dabis F, Van Der Valk M; Hepatocellular Carcinoma Screening Project Working Group for the Collaboration of Observational HIV on behalf of Epidemiological Research Europe (COHERE) In EuroCoord. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV-patients with cirrhosis. *J Viral Hepat*.2019May28.

2020

Atkinson A, Zwahlen M, Barger D, d'Arminio Monforte A, De Wit S, Ghosn J, Girardi E, Svedhem-Johansson V, **Morlat P**, Mussini C, Noguera-Julian A, Stephan C, Touloumi G, Kirk O, Mocroft A, Reiss P, Miro JM, Carpenter JR, Furrer H; Opportunistic Infections Project Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Withholding primary PCP prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE. *Clin Infect Dis*. 2020 May 25;ciaa615. doi: 10.1093/cid/ciaa615. Epub ahead of print. PMID: 32448894.

Late Presentation Working Groups in EuroSIDA and COHERE. Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. *BMC Infect Dis*. 2020 Oct 7;20(1):728. doi: 10.1186/s12879-020-05261-7. PMID: 33028235; PMCID: PMC7541282.

IeDEA and COHERE in EuroCoord Cohort Collaboration. All-cause mortality after antiretroviral therapy initiation in HIV-positive women from Europe, Sub-Saharan Africa and the Americas. *AIDS*. 2020 Feb 1;34(2):277-289. doi: 10.1097/QAD.0000000000002399. PMID: 31876592; PMCID: PMC6948801.

Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Pappas M, **Bonnet F**, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J. Cervical cancer risk in women living with HIV across four continents: A multicohort study. *Int J Cancer*. 2020 Feb 1;146(3):601-609.

II.4. DAD, The Data Collection on Adverse Events of Anti-HIV Drugs N = 66

2003

Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group, Friis-Møller N, Sabin C, Weber R, d'Arminio Monforte A, El-Sadr W, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law M, Kirk O, Phillips AN, Lundgren J. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. *N Engl J Med* 2003;349(21):1993-2003

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, Law MG, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, for the DADSG. Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. *AIDS* 2003;17(8):1179-1193

Law M, Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD, Group DADS. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. *HIV Med* 2003;4(1):1-10

2004

d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Møller N, Writing Committee of the DADSG. Cardio- and cerebrovascular events in HIV-infected persons. *AIDS* 2004;18(13):1811-1817

Fontas E, Van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, D'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, De Wit S, Lundgren JD, Pradier C, Reiss P, Group DADS. Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles? *J Infect Dis* 2004;189(6):1056-1074

2005

Thiébaut R, El-Sadr WM, Friis-Møller N, Rickenbach M, Reiss P, d'Arminio Monforte A, Morfeldt L, Fontas E, Kirk O, De Wit S, Calvo G, Law MG, Dabis F, Sabin CA, Lundgren JD. Predictors of hypertension and changes of blood pressure in HIV-infected patients. *Antivir Ther* 2005;10(7):811-823

2006

Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. *HIV Med* 2006;7(4):218-230

Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, d'Arminio Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. *Arch Intern Med* 2006;166(15):1632-1641

2007

D. A. D. Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr W, Thiébaut R, De Wit S, O K, Fontas E, Law MG, Phillips A, Lundgren JD. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. *N Engl J Med* 2007;356(17):1723-1735

Worm SW, de Wit S, Weber J, Sabin C, Reiss P, El Sadr W, Montforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren J, Friis-Møller N, Group DADS. Does diabetes mellitus (DM) confer an equivalent risk of coronary heart disease (CHD) to pre-existing CHD in HIV-positive individuals? *Antivir Ther* 2007;12(Suppl 2):L10

2008

D. A. D. Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. *AIDS* 2008;22(14):F17-F24

D'Arminio Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Dad. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. *AIDS* 2008;22(16):2143-2153

De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips A. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *Diabetes Care* 2008;31(6):1224-1229

Sabin CA, d'Arminio Monforte A, Friis-Møller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD, Dad. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. *Clin Infect Dis* 2008;46(7):1101-1110

Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD, Dad. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet* 2008;371(9622):1417-1426

2009

Worm SW, de Wit S, Weber R, Sabin C, Reiss P, El-Sadr W, D'Arminio Monforte A, Kirk O, Fontas E, Dabis F, Law M, Lundgren DJ, Friis-Møller N. Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD Study). *Circulation* 2009;119(6):805-811

Worm SW, Sabin C, Reiss P, El-Sadr W, d'Arminio Monforte A, Pradier C, Thiébaut R, Law M, Rickenbach M, De Wit S, Lundgren DJ, Møller NF. Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) than the sum of its components in HIV-infected individuals. Data Collection on Adverse Events of Anti-HIV Drugs (The DAD study). *Diabetes Care* 2009;32(3):474-480

2010

Data Collection on Adverse Events of Anti HIVDSG, Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J. HBV or HCV co-infections and risk of myocardial infarction in HIV-infected individuals: The D:A:D Cohort Study. *Antivir Ther* 2010;15(8):1077-1086

Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG. Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. *Eur J Cardiovasc Prev Rehabil* 2010;17(5):491-501

Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte A, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS* 2010;24(10):1537-1548

Worm SW, Friis-Moller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C, Dad. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. *AIDS* 2010;24(3):427-435

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Montforte AD, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren DJ, Dad. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis* 2010;201(3):318-330

2011

D. A. D. Study Group, Kamara DA, Worm SW, Reiss P, Rickenbach M, Phillips A, Kirk O, D'Arminio Monforte A, Bruyand M, Law M, De Wit S, Smith CJ, Pradier C, Lundgren J, Sabin C. The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study. *J Infect Dis* 2011;204(4):521-525

Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD, EuroSIDA Study G, and the DADSG. The Coding Causes of Death in HIV (CoDe) Project: Initial Results and Evaluation of Methodology. *Epidemiology* 2011;22(4):516-523

Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Moller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). *HIV Med* 2011;12(7):412-421

Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Moller N, Mercie P, Lundgren JD, Sabin C. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. *AIDS* 2011;25(12):1497-1504

2012

Worm S, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, A DAM, Law M, Philipps A, Ryom L, Dabis F, Weber R, Sabin C, Group DADS. Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke. *J Infect Dis* 2012;205(4):535-539

2013

Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R, DAD Study Group. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *Clin Infect Dis*. 2013 Oct 22;56(6):870-9.

Monforte AD, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. *AIDS*. 2013 Jan 28;27(3):407-15.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD, DAD Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. *J Infect Dis*. 2013 May 1;207(9):1359-69.

Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J, D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. *AIDS*. 2013 Nov 13;27(17):2735-48.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fatkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. *BMC Infect Dis*. 2013 Oct 09;13:471.

2014

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. *BMC Nephrol*. 2014 Mar 25;15:51.

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. *HIV Med*. 2014 Nov;15(10):595-603.

Mocroft A, Lundgren J, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Heuhaus J, Fux C, Moranne O, Morlat P, Johnson M, Ryom L; Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study group. A clinically useful risk-score for chronic kidney disease in HIV infection. *J Int AIDS Soc*. 2014 Nov 2;17(4 Suppl 3):19514.

Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, Morlat P, Moranne O, Smith C, El-Sadr W, Law M, Lundgren JD. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. *AIDS*. 2014 Jan 14;28(2):187-99.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Møller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet*. 2014 Jul 19;384(9939):241-8.

2015

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. *J Acquir Immune Defic Syndr*. 2015 Apr 15;68(5):568-77.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. *PLoS Med*. 2015 Mar 31;12(3):e1001809.

2016

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. *HIV Med*. 2016 Apr;17(4):255-68.

Boettiger DC, Sabin CA, Grulich A, Ryom L, Bonnet F, Reiss P, Monforte A, Kirk O, Phillips A, Bower M, Fatkenheuer G, Lundgren JD, Law M, Data collection on Adverse events of Anti HIVDsg. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? *AIDS*. 2016 Jun 19;30(10):1629-37.

Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M; D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. *Eur J Prev Cardiol*. 2016 Jan;23(2):214-23.

Hatleberg CI, Ryom L, El-Sadr W, Smith C, Weber R, Reiss P, Fontas E, Dabis F, Law M, Monforte A, De Wit S, Mocroft A, Phillips A, Lundgren JD, Sabin C, Group DADS. Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. *AIDS*. 2016 Mar 4;30(10):1583-96.

Kamara DA, Smith C, Ryom L, Reiss P, Rickenbach M, Phillips A, Mocroft A, De Wit S, Law M, Monforte AD, Dabis F, Pradier C, Lundgren JD, Sabin C. Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study. *Antivir Ther (Lond)*. 2016;21(6):495-506.

Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F, d'Arminio Monforte A, Smith C, de Wit S, Kirk O, Lundgren JD, Weber R. Antiretroviral Drugs and Risk

of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study (D:A:D). *Open Forum Infect Dis*. 2016 Jan;3(1):ofw009.

Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Miro JM, Vassilenko A, Girardi E, Bruyand M, Obel N, Lundgren JD, Mocroft A, Kirk O, Tb:HIV Study Group in EuroCoord. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. *Lancet HIV*. 2016 Mar;3(3):e120-31.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte A, Kirk O, Ryom L, Data Collection on Adverse events of Anti HIVDS. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. *Lancet HIV*. 2016 Jan;3(1):e23-32.

Ryom L, Lundgren JD, Ross M, Kirk O, Law M, Morlat P, Fontas E, Smit C, Fux CA, Hatleberg CI, de Wit S, Sabin CA, Mocroft A, Group DADS. Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. *J Infect Dis*. 2016 Oct 15;214(8):1212-20.

Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, El-Sadr W, Monforte AD, Mocroft A, Smith C, Fontas E, Dabis F, Phillips A, Sabin C, Group DADS. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. *AIDS*. 2016 Jan 8;30(11):1731-43.

Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren JD; D:A:D Study Group. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. *BMC Med*. 2016 Mar 31;14:61.

2017

Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD. Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. *Aids*. 2017 Jun 01;31(9):1261-70.

Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.D:A:D study group.*AIDS*. 2017 Mar 28. doi: 10.1097 1.

2018

Achhra AC,Sabin C,Ryom L,Hatleberg C,d'Aminio MonforteA,Wit S,PhillipsA,Pradier C,Weber R,Reiss P, El-SadrW, BonnetF, MocroftA,LundgrenJ, Law MG;D:A:D studygroup.Body Mass Indexand The Risk of Serious Non-Aids Events and AllCause Mortality inTreated Hiv-Positive Individuals:D:A:D CohortAnalysis.*JAcquir Immune DeficSyndr*.2018May3.

Hatleberg CI,Ryom L,El-Sadr W, Mocroft A,Reiss P, De Wit S,Dabis F, Pradier C,d'Arminio Monforte A,Kovari H,Law M,Lundgren JD,Sabin CA;Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.Gender differences in the use of cardiovascular interventions

in HIV-positive persons; the D:A:D Study. *J Int AIDS Soc*. 2018 Mar; 21(3).

Hatleberg CI, Ryom L, d'Arminio Monforte A, Fontas E, Reiss P, Kirk O, El-Sadr W, Phillips A, de Wit S, Dabis F, Weber R, Law M, Lundgren JD, Sabin C; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *HIV Med*. 2018 Oct; 19(9):605-618.

Ronit A, Hatleberg CI, Ryom L, Bonnet F, El-Sadr W, Reiss P, Weber R, Pradier C, De Wit S, Law M, Monforte AD, Lundgren J, Mocroft A, Phillips AN, Sabin CA; D:A:D Study group. Associations between serum albumin and serious non-AIDS events among people living with HIV. *AIDS*. 2018 May 28.

Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, Phillips A, Weber R, Fontas E, d'Arminio Monforte A, De Wit S, Dabis F, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. *Lancet HIV*. 2018 Jun; 5(6):e291-e300.

Sabin CA, Ryom L, d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R, Phillips AN, Mocroft A, Bonnet F, Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group. Abacavir use and risk of recurrent myocardial infarction. *AIDS*. 2018 Jan 2; 32(1):79-88.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; D:A:D Study group. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in HIV-positive Persons: The D:A:D Study. *Clin Infect Dis*. 2018 Jun 14.

2019

Hatleberg CI, Ryom L, Kamara D, De Wit S, Law M, Phillips A, Reiss P, D'Arminio Monforte A, Mocroft A, Pradier C, Kirk O, Kovari H, **Bonnet F**, El-Sadr W, Lundgren JD, Sabin C; D:A:D Study Group. Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. *EClinicalMedicine*. 2019 Aug 11; 13:91-100.

Ryom L, Lundgren JD, Law M, Kirk O, El-Sadr W, **Bonnet F**, Weber R, Fontas E, Monforte AD, Phillips A, Reiss P, de Wit S, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group. Serious clinical events in HIV-positive persons with chronic kidney disease. *AIDS*. 2019 Nov 15; 33(14):2173-2188.

Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, Ross M, **Morlat P**, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. *J Infect Dis*. 2019 Oct 8; 220(10):1629-1634.

Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Sabin C, Bower M, Bonnet F, Reiss P, de Wit S, Pradier C, Weber R, El-Sadr W, Lundgren J, Mocroft A; Data

Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. *Clin Infect Dis*. 2019 Feb 1;68(4):650-657.

Wandeler G, Mauren E, Atkinson A, Dufour JF, Kraus D, Reiss P, Peters L, Dabis F, Fehr J, Bernasconi E, van der Valk M, Smit C, Gærde LK, Rockstroh J, Neau D, Bonnet F, Rauch A; Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. *J Hepatol*. 2019 Apr 6. pii: S01688278(19)30226-0.

2020

d'Arminio Monforte A, Bonnet F, Bucher HC, Pourcher V, Pantazis N, Pelchen-Matthews A, Touloumi G, Wolf E. What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. *HIV Med*. 2020 Sep;21 Suppl 2:3-16. doi: 10.1111/hiv.12935. PMID: 32881311.

Ryom L, Lundgren JD, Reiss P, Ross M, Kirk O, Fux CA, Morlat P, Fontas E, Smith C, De Wit S, d'Arminio Monforte A, El Sadr W, Hatleberg C, Phillips A, Sabin C, Law M, Mocroft A; D:A:D Study Group. The impact of immunosuppression on chronic kidney disease in people living with HIV; the D:A:D study. *J Infect Dis*. 2020 Jul 8:jiaa396. doi: 10.1093/infdis/jiaa396. Epub ahead of print. PMID: 32640015

II.5. EuroSIDA

N = 83

2004

Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. *Antivir Ther* 2004;9(5):787-800

d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J. Changing incidence of central nervous system diseases in the EuroSIDA cohort. *Ann Neurol* 2004;55(3):320-328

Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, Mercey D, Machala L, Horban A, Lundgren JD. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. *J Infect Dis* 2004;190(1):148-155

Kirk O, Mocroft A, Lundgren JD. [Decline in AIDS and death rates in the EuroSIDA study. An observational study]. *Ugeskr Laeger* 2004;166(26-31):2572-2576

Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J, EuroSIDA study group. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. *AIDS* 2004;18(17):2333-2337

Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. *Cancer* 2004;100(12):2644-2654

Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. *J Infect Dis* 2004;190(11):1947-1956

Mocroft A, Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, Blaxhult A, Mulcahy F, Gatell JM, Lundgren JD. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. *HIV Med* 2004;5(6):437-447

Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulcahy F, Fisher M, Machala L, Lundgren JD, EuroSIDA study Group. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. *AIDS* 2004;18(13):1795-1804

Yust I, Fox Z, Burke M, Johnson A, Turner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. *Eur J Clin Microbiol Infect Dis* 2004;23(7):550-559

2005

Carter M. EuroSIDA cohort: 9% coinfectd with HIV/HBV. IAPAC Mon 2005;11(4):110

Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD, EuroSIDA study group. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. *Antivir Ther* 2005;10(7):791-802

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, O K, Lundgren JD, EuroSIDA study Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. *AIDS* 2005;19(6):593-601

Mocroft A, Oancea C, van Lunzen J, Vanhems P, Banhegyi D, Chiesi A, Vinogradova E, Maayan S, Phillips AN, Lundgren J, EuroSIDA study group. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. *Am J Gastroenterol* 2005;100(7):1446-1454

Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? *Antivir Ther* 2005;10(7):779-790

Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JD, EuroSIDA study group. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? *AIDS* 2005;19(18):2117-2125

Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis* 2005;192(6):992-1002

2006

Bannister WP, Kirk O, Gatell JM, Knysz B, Viard JP, Mens H, Monforte AD, Phillips AN, Mocroft A, Lundgren JD, EuroSIDA study group. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. *J Acquir Immune Defic Syndr* 2006;42(2):229-237

Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A, EuroSIDA study group. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. *Antivir Ther* 2006;11(6):707-715

Mocroft A, Horban A, Clumeck N, Stellbrink HJ, Montforte AD, Zilmer K, Kirk O, Gatell J, Phillip A, Lundgren DJ, EuroSIDA study Group. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000. *HIV Clin Trials* 2006;7(6):271-284

Mocroft A, Neaton J, Bebhuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren JD. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. *Clin Trials* 2006;3(2):119-132

Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A, Phillips AN, Lundgren JD. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. *Scand J Infect Dis* 2006;38(11-12):1092-1097

Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. *J Infect Dis* 2006;194(5):633-641

Rockstroh JK. Influence of viral hepatitis on HIV infection. *J Hepatol* 2006;44(1 Suppl):S25-S27

2007

Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, Mocroft A, Phillips AN, Olsen CH, Gatell JM, Gunthard HF, Reiss P, Perno CF, Clotet B, Lundgren JD, EuroSIDA study group. Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. *J Infect Dis* 2007;196(8):1180-1190

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD, EuroSIDA study group. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. *AIDS* 2007;21(6):721-732

Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD, EuroSIDA study group. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. *AIDS* 2007;21(15):2033-2042

Hill A, Grossman H, Cohen C, Nadler J, Peeters M. Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial. *HIV Clin Trials* 2007;8(2):68-76

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD, EuroSIDA study group. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. *HIV Med* 2007;8(2):96-104

Kowalska JD, Mocroft A, Blaxhult A, Colebunders R, van Lunzen J, Podlekareva D, Hansen AB, Machala L, Yust I, Benfield T, EuroSIDA study group. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. *AIDS Res Hum Retroviruses* 2007;23(10):1183-1188

Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD, EuroSida Study Group. Chronic renal failure among HIV-1-infected patients. *AIDS* 2007;21(9):1119-1127

Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD, EuroSida Study Group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. *Lancet* 2007;370(9585):407-413

2008

Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. *J Acquir Immune Defic Syndr* 2008;48(3):324-33

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte A, Clotet B, Lundgren JD. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. *AIDS* 2008;22(3):367-376

Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD, EuroSIDA study group. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. *AIDS* 2008;22(16):2187-2198

Fessel J, Hurley LB. Incidence of pancreatitis in HIV-infected patients: comment on findings in EuroSIDA cohort. *AIDS* 2008;22(1):145-147

Mocroft A, Horban A, Clotet B, d'Arminio Monforte A, Bogner JR, Aldins P, Staub T, Antunes F, Katlama C, Lundgren JD. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. *HIV Med* 2008;9(1):41-46

Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD. Loss to follow-up in an international, multicentre observational study. *HIV Med* 2008;9(5):261-269

Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O. The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. *Cent Eur J Public Health* 2008;16(3):99-105

Reekie J, Mocroft A, Kirk O, Lundgren DJ. The clinical application of the EuroSIDA risk score. *AIDS & Hepatitis Digest* 2008;126:1-5

Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? *AIDS* 2008;22(17):2381-2390

Smith CJ, Mocroft A, Lundgren JD. Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. *AIDS* 2008;22(8):997-998

Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. *J Infect Dis* 2008;198(9):1337-1344

2009

Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD, EuroSIDA study Group. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. *J Acquir Immune Defic Syndr* 2009;50(5):457-63

van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. *Antivir Ther* 2009;14(1):75-83

Young J, Bucher HC, Guenthard HF, Rickenbach M, Fux CA, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Battegay M. Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. *Antivir Ther* 2009;14(6):771-779

2010

Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. *AIDS* 2010;24(11):1667-1678

Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. *Antivir Ther* 2010;15(4):563-570

Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. *J Acquir Immune Defic Syndr* 2010;55(2):262-270

Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. *HIV Med* 2010;11(7):469-478

Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte A, Flisiak R, Lundgren J. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. *J Antimicrob Chemother* 2010;65(3):548-555

Trullas JC, Mocroft A, Cofan F, Turret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miro JME. Dialysis and renal transplantation in HIV-infected patients: a European survey. *J Acquir Immune Defic Syndr* 2010;55(5):582-589

2011

Bannister WP, Cozzi-Lepri A, Kjaer J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. *J Antimicrob Chemother* 2011;66(4):901-911

Cozzi-Lepri A, Prosperi MC, Kjaer J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D. Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. *PLoS One* 2011;6(11):e25665

Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. *AIDS* 2011;25(12):1505-1513

Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Banhegyi D, Clotet B, Lundgren J, Menendez-Arias L, Martinez-Picado J. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. *J Infect Dis* 2011;204(5):741-752

Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. *AIDS* 2011;25(18):2259-2268

Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Hepatitis delta in HIV-infected individuals in Europe. *AIDS* 2011;25(16):1987-1992

Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. *AIDS* 2011;25(10):1305-1315

2012

Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD, EuroSIDA in EuroCoord. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. *HIV Med* 2012;13(1):62-72

Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. *AIDS* 2012;26(3):315-23

Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. *AIDS* 2012;26(15):1917-1926

Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O. Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. *BMC Infect Dis* 2012;12(1):229

Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. *PLoS One* 2012;7(7):e41673

Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. *Antivir Ther* 2012 Epub

2013

Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. *HIV Med.* 2013 Nov;14(10):614-23.

Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD, EuroSIDA study in EuroCOORD. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. *AIDS.* 2013 Mar 27;27(6):907-18.

Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD, for EuroSida in EuroCoord. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfecting patients. *PLoS One.* 2013 8(5):e64283.

Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte A, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? *J Hepatol.* 2013 Aug;59(2):213-20.

Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM, Mocroft A, EuroSIDA in EuroCoord. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. *HIV Med.* 2013 Sep;14(8):503-8.

Sogaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, Servitskiy S, Domingo P, Reiss P, Mocroft A, Kirk O. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. *J Infect.* 2013 May;66(5):439-46.

2014

Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. *Infection.* 2014 Aug;42(4):757-62.

Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD. Deteriorating renal function and clinical

outcomes in HIV-positive persons. *AIDS*. 2014 Mar 13;28(5):727-37.

Mocroft A, Ryom L, Reiss P, Furrer H, D'Arminio Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren JD, Kirk O; EuroSIDA in EuroCOORD. A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. *HIV Med*. 2014 Mar;15(3):144-52.

Peters L, Mocroft A, Soriano V, Rockstroh JK, Kirkby N, Reiss P, Katlama C, Zakharova N, Flisiak R, Lundgren JD; EuroSIDA in EuroCoord. High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. *HIV Med*. 2014 Nov;15(10):615-20.

Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP; EuroSIDA in EuroCOORD. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. *J Infect Dis*. 2014 Jul 15;210(2):234-43.

Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J; EuroSIDA in EuroCoord. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. *PLoS One*. 2014 Jan 31;9(1):e87160.

2015

Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O, Mocroft A, Peters L, Rockstroh JK; EuroSIDA in EuroCoord. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? *Liver Int* 2015;35(11):2384-91.

Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Liver-related death among HIV/HCV coinfecting individuals, implications for the era of directly acting antivirals. *AIDS* 2015;29(10):1205-15.

Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M, Parczewski M, Lundgren JD, Mocroft A, Kirk O; EuroSIDA in EuroCoord. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. *HIV Med*. 2015 Oct;16(9):533-43.

Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A; EuroSIDA in EuroCOORD. HIV resistance testing and detected drug resistance in Europe. *AIDS* 2015;29(11):1379-89.

2016

/

2017

/

2018

/

Autre Collaboration

N = 26

2000

International Collaboration on HIV and Cancer, Appelby P, Beral V, Carpenter L, Casabonne D, Deo H, Langston N, Newton R, Reeves G. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. *J Natl Cancer Inst* 2000;92(22):1823-1830

2002

van Benthem BH, Vernazza P, Coutinho RA, Prins M, for the European Study on the Natural History of HIV Infection in Women, the Swiss HIV Cohort Study. The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women. *AIDS* 2002;16(6):919-924

2003

Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. *Lancet* 2003;361(9359):726-735

Carr A, Law M, HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. *J Acquir Immune Defic Syndr* 2003;33(5):571-576

Ioannidis JPA, Trikalinos TA, Law M, Carr A, HIV Lipodystrophy Case Definition Study Group. HIV lipodystrophy case definition using artificial neural network modelling. *Antivir Ther* 2003;8(5):435-441

2004

/

2006

Puoti M, Cozzi-Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winrock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, d'Arminio Monforte A, HBV-HIV International Intercohort Study Group. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. *Antivir Ther* 2006;11(5):567-574

2007

Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F, GECSA, Australian HIV Observational Database, St Vincent's Hospital Cohort study group. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. *HIV Med* 2007;8(3):171-180

2008

Drylewicz J, Matheron S, Lazaro E, Damon D, Bonnet F, Simon F, Dabis F, Brun-Vezinet F, Chêne G, Thiébaud R. Comparison of Viro-Immunologic Markers Evolution between HIV-1 and HIV-2 Infected Patients in France from the ANRS CO 3 Aquitaine and CO 5 HIV-2 cohorts. *AIDS* 2008;22(4):457-468

2009

When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, d'Arminio Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole SR, Brodt HR, Casabona J, Chêne G, del Amo J, Guest J, Kitahata M, Lampe F, Mocroft A, Reiss P. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 2009;373(9672):1352-1363

2011

Franrenet S, Moutel G, Raffi F, Dabis F, Bruyand M, Herve C, Leport C, Duchange N. Information that should be given to HIV cohort participants during ongoing research: the viewpoints of patient representatives and research professionals. *J Empir Res Hum Res Ethics* 2011;6(4):76-83

Judd A, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. *AIDS* 2011;25(18):2279-2287

2012

/

2014

Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczar D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA; **HIV-CAUSAL Collaboration**. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. *Neurology*. 2014 Jul 8;83(2):134-41.

Luz PM, Bruyand M, Ribeiro S, Bonnet F, Moreira RI, Hessamfar M, Campos DP, Greib C, Cazanave C, Veloso VG, Dabis F, Grinsztejn B, Chêne G; **IPEC/FIOCRUZ Cohort and the Aquitaine ANRS C03 Study Group**. AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies. *BMC Infect Dis*. 2014 May 21;14:278.

Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; **HIV/TB study group**. Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. *Eur Respir J*. 2014 Jan;43(1):166-77.

2015

Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Pappas V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA ; **HIV-CAUSAL Collaboration**. Boosted Lopinavir-versus boosted Atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis*. 2015;60(8):1262-8.

Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ. Low-frequency drug-resistant HIV-1 and risk of

virological failure to first-line NNRTI-based antiretroviral therapy: A multi-cohort European case-control study using centralized ultrasensitive 454 pyrosequencing. *J Antimicrob Chemother* 2015;70(3):930-40.

Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, Losso MH, Toibaro J, Skrahin A, Miro JM, Caylà JA, Girardi E, Bruyand M, Obel N, Podlekareva DN, Lundgren JD, Mocroft A, Kirk O; **TB:HIV study group in EuroCoord**. Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. *PLoS One*. 2015 Dec 30;10(12):e0145380.

Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d'Arminio A, Cavassini M, Smith C, Justice AC, Gill J, Sterne JA, Obel N. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. *AIDS* 2015;29(2):221-9.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; **HIV-CAUSAL Collaboration**. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV*. 2015;2(8):e335-43.

Mansfeld M, Skrahina A, Shepherd L, Schultze A, Panteleev AM, Miller RF, Miro JM, Zeltina I, Tetrarov S, Furrer H, Kirk O, Grzeszczuk A, Bolokadze N, Matteelli A, Post FA, Lundgren JD, Mocroft A, Efsen A, Podlekareva DN; **TB:HIV study group in EuroCoord**. Major differences in organisation and availability of health care and medicines for HIV/TB coinfectd patients across Europe. *HIV Med*. 2015 Oct;16(9):544-52.

2016

Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernan MA, Center for AIDS Research Network of Integrated Clinical Systems and **the HIV-CAUSAL Collaboration**. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. *J Acquir Immune Defic Syndr*. 2016 Jun 1;72(2):214-21.

Ngo Giang Huong N*, Wittkop L* (*co-first author), Judd A, Reiss P, Goetghebuer T, Duiculescu D, Noguera-Julian A, Marczyńska M, Giacchino C, Ene L, Ramos JT, Cellera C, Klimkait T, Brichard B, Valerius N, Sabin C, Teira T, Obel N, Stephan C, de Wit S, Thorne C, Gibb D, Schwimmer C, Athena Campbell M, Pillay D, Lallemand M. Prevalence and effect of pre-existing drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a **EuroCoord-CHAIN-EPPICC joint project**. *BMC Infect Dis*. 2016 Nov 8;16(1):654.

2017

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly prescribed antiretroviral therapy

regimens and incidence of AIDS-defining neurological conditions. J Acquir Immune Defic Syndr. 2017 Oct 4.

Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RD, Reiss P; **HIV-CAUSAL Collaboration**; Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV. 2017 Apr 11.

Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA.. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):311–8.

2018

/

2019

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage III GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. Stat Med. 2019 Jun 15;38(13):2428-2446.